Search Result
Results for "
oral carcinoma
" in MedChemExpress (MCE) Product Catalog:
5
Biochemical Assay Reagents
9
Isotope-Labeled Compounds
| Cat. No. |
Nombre del producto |
Target |
Áreas de investigación |
Chemical Structure |
-
- HY-50767
-
|
PD 0332991
|
CDK
|
Cancer
|
|
Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
|
-
-
- HY-101840
-
-
-
- HY-125840
-
|
PT2977; MK-6482
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .
|
-
-
- HY-50767C
-
|
PD-0332991 hydrochloride
|
CDK
|
Cancer
|
|
Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
|
-
-
- HY-16706
-
|
|
Histone Acetyltransferase
|
Cancer
|
|
Remodelin is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model .
|
-
-
- HY-100492
-
|
BLU-554
|
FGFR
|
Cancer
|
|
Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling .
|
-
-
- HY-114338
-
|
SHR-6390
|
CDK
|
Cancer
|
|
Dalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .
|
-
-
- HY-111458
-
|
|
Deubiquitinase
|
Cancer
|
|
GSK2643943A is a deubiquitinating enzyme (DUB) inhibitor targeting USP20. GSK2643943A has affinity with an IC50 of 160 nM for USP20/Ub-Rho. GSK2643943A has anti-tumor efficacy and can be used for the research of oral squamous cell carcinoma (OSCC) .
|
-
-
- HY-101840A
-
|
L593754 hydrochloride; MH 12-43 hydrochloride; Ethylisopropylamiloride hydrochloride
|
TRP Channel
Autophagy
COX
Prostaglandin Receptor
Na+/H+ Exchanger (NHE)
|
Inflammation/Immunology
Cancer
|
|
EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na +/H +-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma .
|
-
-
- HY-159642
-
|
TYRA-300
|
FGFR
ERK
|
Metabolic Disease
Cancer
|
|
Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
|
-
-
- HY-N2414
-
-
-
- HY-111226
-
-
-
- HY-103706
-
ROC-325
3 Publications Verification
|
Autophagy
Apoptosis
|
Cancer
|
|
ROC-325 is a potent and orally active autophagy inhibitor with a strong anticancer activity. ROC-325 induces the deacidification of lysosomes, accumulation of autophagosomes, and disrupted autophagic flux. ROC-325 also induces renal cell carcinoma apoptosis .
|
-
-
- HY-13593
-
|
CB-1348; WR-139013
|
DNA Alkylator/Crosslinker
|
Neurological Disease
Cancer
|
|
Chlorambucil (CB-1348), an orally active antineoplastic agent, is a CNS-penetrant bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .
|
-
-
- HY-150072
-
|
|
PKA
|
Cancer
|
|
DS89002333 is an orally active and potent PRKACA inhibitor, with an IC50 of 0.3 nM. DS89002333 shows good anti-tumor activity in an FL-HCC patient-derived xenograft model (expressing the DNAJB1-PRKACA fusion gene). DS89002333 can be used in study of fibrolamellar hepatocellular carcinoma (FL-HCC) .
|
-
-
- HY-N2123
-
|
|
Caspase
|
Neurological Disease
Cancer
|
|
Neoliquiritin is a flavonoid and flavanone-derived cytotoxic agent with anticancer activity and neuroprotective effects. Neoliquiritin exhibits excellent tumor specificity, exerting a more pronounced killing effect on cancer cells compared with normal oral cells. Neoliquiritin also exerts neuroprotective effects by inhibiting ATP depletion and the elevation of caspase 3/7 activity. Widely present in the roots of Glycyrrhiza uralensis, Glycyrrhiza inflata and Glycyrrhiza glabra, Neoliquiritin can be applied to studies on human oral squamous cell carcinoma, leukemia, Parkinson's disease and other conditions .
|
-
-
- HY-139434
-
|
|
Histone Demethylase
|
Cancer
|
|
JMJD6-IN-1 is a JMJD6 inhibitor, with an inhibition rate of 82% at 10 μM. JMJD6-IN-1 inhibits MCF-7 and HCC4006 cell proliferation with IC50 values of 19.2 μM and 25.2 μM. JMJD6-IN-1 inhibits JMJD6 demethylase activity. JMJD6-IN-1 can be used for the research of lung adenocarcinoma, prostate cancer, breast cancer, pancreatic cancer, colon cancer, oral squamous cell carcinoma, and glioblastoma .
|
-
-
- HY-153967
-
BLU0588
2 Publications Verification
|
PKA
|
Cancer
|
|
BLU0588 is an orally active, potent and selective PRKACA (protein kinase cAMP-activated catalytic subunit alpha) kinase inhibitor, with an IC50 of 1 nM and dissociation constant (Kd) of 4 nM. BLU0588 can be used for fibrolamellar carcinoma (FLC) research .
|
-
-
- HY-160215
-
|
|
TGF-β Receptor
p38 MAPK
TGF-beta/Smad
Interleukin Related
|
Cancer
|
|
GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .
|
-
-
- HY-114338A
-
|
SHR-6390 hydrochloride
|
CDK
|
Cancer
|
|
Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .
|
-
-
- HY-17493
-
|
|
MDM-2/p53
Apoptosis
|
Neurological Disease
Cancer
|
|
MI-773 is an orally active, selective MDM2-p53 interaction inhibitor with a Ki of 0.88 nM for MDM2. MI-773 blocks the MDM2-TP53 interaction. MI-773 potently activates p53. MI-773 induces Apoptosis. MI-773 causes tumor regression in xenograft models of adenoid cystic carcinoma. MI-773 exhibits anticancer effects in neuroblastoma. MI-773 TFA can be used for the research of adenoid cystic carcinoma .
|
-
-
- HY-119198
-
|
|
Apoptosis
Histone Methyltransferase
|
Cancer
|
|
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers .
|
-
-
- HY-103317A
-
|
|
Calcium Channel
|
Cardiovascular Disease
Cancer
|
|
NAADP tetrasodium is a second messenger. NAADP tetrasodium releases Ca 2+ from acidic endosomes and lysosomes. NAADP tetrasodium can be used to study cancer (such as oral squamous cell carcinoma, malignant melanoma) and angiogenesis-related diseases .
|
-
-
- HY-P1654
-
|
|
Integrin
|
Cancer
|
|
A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .
|
-
-
- HY-157231A
-
|
|
PERK
|
Cancer
|
|
HC-5404-Fu is an orally active PERK inhibitor with an IC50 of 0.001 μM against human PERK. HC-5404-Fu blocks PERK activation induced by VEGFR-TKI and disrupts the adaptive stress response triggered by VEGFR-TKI. HC-5404-Fu enhances anti-angiogenic effects by inhibiting newly formed and mature tumor blood vessels in renal cell carcinoma models. HC-5404-Fu can be used in research related to renal cell carcinoma .
|
-
-
- HY-163959
-
|
|
PNPLA3
|
Metabolic Disease
Cancer
|
|
PF-07853578 is an orally active PNPLA3 modulator. PF-07853578 significantly reduces human PNPLA3-I148M protein levels and effectively decreases hepatic triglyceride content by reducing this mutant protein. PNPLA3 degrader-1 can be used in the research of liver cirrhosis and hepatocellular carcinoma .
|
-
-
- HY-N6726
-
|
|
Fungal
Endogenous Metabolite
|
Infection
Cancer
|
|
Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
|
-
-
- HY-N0746
-
|
|
Others
|
Cancer
|
|
Oxysophocarpine is an alkaloid extracted from Sophora alopecuroides.?Oxysophocarpine has neuroprotective and anti-nociceptive effects on the central and peripheral nervous systems . Oxysophocarpine inhibits the?growth?and?metastasis?of ?oral?squamous?cell?carcinoma?(OSCC) .
|
-
-
- HY-101246
-
|
|
RET
|
Cancer
|
|
RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity .
|
-
-
- HY-14653
-
|
TAC-101; Am 555S
|
RAR/RXR
Apoptosis
|
Cancer
|
|
Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with Ki of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer .
|
-
-
- HY-Y1155
-
-
-
- HY-N8420
-
|
|
Fungal
|
Infection
Cancer
|
|
Thalifoline is an isoquinoline alkaloid. Thalifoline exerts cytotoxic effects on cancer cells. Thalifoline inhibits the growth of Fusarium oxysporum f. sp. lycopersici. Thalifoline can be used in research related to lung adenocarcinoma, colon cancer, oral epidermoid carcinoma, and fungal infections .
|
-
-
- HY-W599279
-
|
|
Molecular Glues
NEKs
|
Cancer
|
|
ABS-752 is a potent and orally active GSPT1 and NEK7 molecular glue degrader. ABS-752 shows cytotoxicity. ABS-752 decreases the protein expression of GSPT1 and SALL4, NEK7. ABS-752 is a prodrug activated by the monoamine oxidase, VAP-1, to an aldehyde intermediate and subsequently to the active molecule, ABT-002 (HY-175283). ABS-752 has the potential for the research of hepatocellular carcinoma .
|
-
-
- HY-P2302
-
|
|
Antibiotic
Bacterial
Fungal
|
Infection
Inflammation/Immunology
Cancer
|
|
Defensin HNP-3 human is an α-defensin stored in the azurophilic granules of human neutrophils. Defensin HNP-3 human exerts broad-spectrum bactericidal, antifungal and antiviral activities mainly by forming bacterial membrane pores, and acts as a chemoattractant for monocytes and T cells. Defensin HNP-3 human maintains epithelial integrity to support periodontal tissue homeostasis, and exerts concentration-dependent effects on epithelial cell proliferation, adhesion and bacterial adhesion. Defensin HNP-3 human targets solid tumors and leukemia by inducing single-strand DNA breaks and membrane permeabilization in tumor cells via electrostatic binding and pore formation. Defensin HNP-3 human is abundant in human tongue squamous cell carcinoma and neutrophils infiltrating oral squamous cell carcinoma. Defensin HNP-3 human can be applied to research related to periodontitis and human tongue squamous cell carcinoma .
|
-
-
- HY-P4087
-
|
|
HIV
|
Infection
Cancer
|
|
Cys(Npys)-(Arg)9 is a synthetic cationic cell-penetrating peptide with a reversible thiol-reactive nitropyridyl (Npys) group. Cys(Npys)-(Arg)9 efficiently mediates the internalization and delivery of various "cargo" such as proteins and antibodies by forming reversible disulfide bonds with surface-exposed cysteine residues. Cys(Npys)-(Arg)9 endows TALEN proteins with cell-penetrating activity, enabling gene knockout in mammalian cells and protein transduction in wheat microspores. Cys(Npys)-(Arg)9 can be conjugated with antibodies to form cationized IgG for enhancing endosomal escape of oligonucleotides, or form siRNA delivery complexes. When the molar ratio of Cys(Npys)-(Arg)9 to loaded molecules is higher than 1:1, it exerts certain cytotoxic effects on cells. Cys(Npys)-(Arg)9 can be used in studies related to oral squamous cell carcinoma and HIV infection .
|
-
-
- HY-172423
-
|
KO-2806
|
Farnesyl Transferase
mTOR
VEGFR
|
Cancer
|
|
Darlifarnib (KO-2806) is an orally active farnesyl transferase inhibitor. Darlifarnib inhibits the mTORC1 signaling pathway, thereby enhancing the anti-angiogenic properties of tyrosine kinase inhibitors. When used in combination with anti-VEGFR tyrosine kinase inhibitors, Darlifarnib promotes renal cell carcinoma tumor regression and inhibits tumor neovascularization. Darlifarnib sensitizes renal cell carcinoma tumors that progress after anti-VEGFR TKI treatment .
|
-
-
- HY-W010593
-
|
|
Environmental Pollutants
Drug Metabolite
|
Cancer
|
|
Ethylenethiourea is a degradation product of the ethylenebisthiocarbamate group of fungicides. Ethylenethiourea is tumorigenic and teratogenic. Ethylenethiourea is orally active .
|
-
-
- HY-119425
-
|
ICRF 159
|
Topoisomerase
|
Cancer
|
|
Razoxane (ICRF 159), a EDTA (HY-Y0682) derivative, is an orally active antiangiogenic topoisomerase II inhibitor. Razoxane has antineoplastic, antiangiogenic, and antimetastatic activities. Razoxanecan be used for the research of renal cell carcinoma (RCC), lung cancer and melanoma cancer .
|
-
-
- HY-111226A
-
-
-
- HY-106735
-
|
Ro 13-6298; Arotinoid ethyl ester
|
RAR/RXR
|
Inflammation/Immunology
Cancer
|
|
Arotinoid (RO 13-6298) is a retinoid, and acts as an orally active and highly potent agonist of retinoic acid receptors (RARs) with antipsoriatic effects. Arotinoid has antipapiltoma activity with an ED50 of 0.05 mg/kg. Arotinoid can be used for the research of skin carcinomas .
|
-
-
- HY-112532
-
|
|
Leukotriene Receptor
Lipoxygenase
|
Inflammation/Immunology
Cancer
|
|
REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a Ki of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved. REV 5901 can be used for the study of colon carcinoma .
|
-
-
- HY-145835
-
|
|
PERK
|
Cancer
|
|
PERK-IN-5 is a highly potent, selectively and orally bioavailable PERK inhibitor (IC50s of 2 and 9 nM for PERK and p-eIF2α, respectively). PERK-IN-5 can significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft tumor model .
|
-
-
- HY-106364
-
|
Bleomycin PEP; Pepleomycin
|
Apoptosis
Antibiotic
|
Cancer
|
|
Peplomycin (Bleomycin PEP) is an analog of Bleomycin (HY-108345) and an antitumor antibiotic. Peplomycin exhibits potent antitumor activity and relatively low pulmonary toxicity. Peplomycin can induce various skin abnormalities and trigger apoptosis in SSCKN cells of oral squamous cell carcinoma. Peplomycin can also induce pulmonary fibrosis. Peplomycin is applicable for the research of tumors, pulmonary fibrosis and other related diseases .
|
-
-
- HY-179387
-
|
|
CXCR
Autophagy
NOD-like Receptor (NLR)
Reactive Oxygen Species (ROS)
Apoptosis
|
Cancer
|
|
CXCR2-IN-3 is a CXCR2 inhibitor with an IC50 of 11.37 μM. CXCR2-IN-3 mediates CXCR2-Ca 2+ signalling inhibition halted autophagic flux, subsequently facilitating ROS-mediated apoptotic cell death. CXCR2-IN-3 suppresses the CXCR2-NLRP3 canonical pathway, suppressing pre-tumorigenic markers. CXCR2-IN-3 causes autophagy-dependent cell death in polyploid giant cancer cells (PGCCs). CXCR2-IN-3 can be used for the research of oral squamous cell carcinoma (OSCC) .
|
-
-
- HY-151461
-
|
|
Arf Family GTPase
|
Cancer
|
|
CHNQD-01255 is an orally active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy .
|
-
-
- HY-N1261
-
|
|
Others
|
Cancer
|
|
Scutebarbatine B shows significant cytotoxic activities against three human cancer lines, namely, HONE-1 nasopharyngeal, KB oral epidermoid carcinoma, and HT29 colorectal carcinoma cells, with IC50 values in the range 3.5-8.1 mM [1]<
|
-
-
- HY-171450
-
|
|
Trk Receptor
|
Cancer
|
|
VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma .
|
-
-
- HY-N0530
-
|
Dryocrassin
|
Apoptosis
Influenza Virus
|
Cancer
|
|
Dryocrassin ABBA (Dryocrassin) is an orally active phloroglucinol derivative that can be extracted from Phyllopteris officinalis. Dryocrassin ABBA has antitumor and antiviral activity. Dryocrassin ABBA induced apoptosis of human hepatocellular carcinoma cells through mitochondrial pathway mediated by Caspase .
|
-
-
- HY-N15199
-
|
|
Others
|
Cancer
|
|
Schisanlactone A is a natural triterpenoid compound. Schisanlactone A has moderate cytotoxicity, with its IC50 value being 63.3 μM against KB cells. Schisanlactone A does not possess antibacterial or tyrosinase inhibitory activities. Schisanlactone A can be used for the study of oral epidermoid carcinoma .
|
-
-
- HY-144614
-
|
|
DYRK
Apoptosis
|
Neurological Disease
Cancer
|
|
JH-XVII-10 is a potent, selective and orally active DYRK1A and DYRK1B inhibitor with IC50s of 3 nM and 5 nM for DYRK1A and DYRK1B, respectively. JH-XVII-10 shows antitumor efficacy in neck squamous cell carcinoma (HNSCC) cell lines .
|
-
- HY-50767B
-
|
PD-0332991 dihydrochloride
|
CDK
|
Cancer
|
|
Palbociclib (PD 0332991) dihydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib dihydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
|
-
- HY-10320G
-
|
BIRB 796 (GMP)
|
p38 MAPK
|
Cancer
|
|
Doramapimod GMP (BIRB 796 GMP) is an orally active inhibitor for p38 MAPK, with IC50s of 38, 65, 200 and 520 nM, for p38α, p38β, p38γ, p38δ. Doramapimod exhibits cytotoxicity and antitumor activity against multiple myeloma, synergizes with multidrug resistance protein 1 (ABCB1) and aurora kinase inhibitor VX680, promoting their antitumor efficacy against oral epidermoid carcinoma and cervical cancer. Doramapimod also exhibits anti-inflammatory activity .
|
-
- HY-114594
-
-
- HY-N4308
-
|
Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone
|
NF-κB
IKK
Bcl-2 Family
|
Cancer
|
|
Hexamethylquercetagetin (Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone) is an orally active NF-κB inhibitor. Hexamethylquercetagetin inhibits NF-κB-derived luciferase activity, reduces phosphorylated p65 and IκBα, Cyclin D1, Bcl-2 and blocks TNFα-induced NF-κB activation. Hexamethylquercetagetin inhibits survival and proliferation of cervical carcinoma cells. Hexamethylquercetagetin suppresses tumor volume and weight in BALB/c nude mouse xenograft models of cervical carcinoma. Hexamethylquercetagetin can be used for the research of cancer, such as cervical carcinoma .
|
-
- HY-160215A
-
|
|
TGF-β Receptor
p38 MAPK
TGF-beta/Smad
Interleukin Related
|
Cancer
|
|
GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .
|
-
- HY-N0746R
-
|
|
Reference Standards
Others
|
Cancer
|
|
Oxysophocarpine (Standard) is the analytical standard of Oxysophocarpine. This product is intended for research and analytical applications. Oxysophocarpine is an alkaloid extracted from Sophora alopecuroides. Oxysophocarpine has neuroprotective and anti-nociceptive effects on the central and peripheral nervous systems . Oxysophocarpine inhibits the growth and metastasis of oral squamous cell carcinoma (OSCC) .
|
-
- HY-176907
-
|
|
E1/E2/E3 Enzyme
|
Cancer
|
|
ML-93 is an orally active SAE inhibitor, with an IC50 value of 0.4 μM. ML-93 inhibits the SUMOylation pathway in HCT116 cells. ML-93 shows robust antitumor activity in the HCT116 colorectal carcinoma xenograft model. ML-93 can be used for the study of colorectal cancer .
|
-
- HY-175589
-
|
|
Topoisomerase
Apoptosis
Bcl-2 Family
|
Cancer
|
|
XSJ81 is an orally active anti-cancer agent. XSJ81 significantly inhibits the proliferation of ampullary carcinoma (AC) DPC-X3 cells with an IC50 of 0.655 μM. XSJ81 inhibits the colony formation, arrests cell cycle at the G2/M phase and inhibits the migration in DPC-X3 cells. XSJ81 induces DNA damage and apoptosis in DPC-X3 cells. XSJ81 demonstrates significant anti-tumor efficacy in mice bearing DPC-X3 xenografts. XSJ81 can be used for the study of ampullary carcinoma .
|
-
- HY-120412
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
SKLB188 is an orally active and potent epidermal growth factor receptor (EGFR) inhibitor (IC50=5 nM). SKLB188 suppresses MEK/Erk and Akt/mTOR signaling pathways to inhibit head and neck squamous cell carcinoma (HNSCC) proliferation and induce caspase-dependent apoptosis. SKLB188 is promising for research of EGFR-overexpressing solid tumors .
|
-
- HY-177134
-
|
|
VEGFR
c-Met/HGFR
|
Cancer
|
|
Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .
|
-
- HY-170647
-
|
|
Ras
|
Cancer
|
|
SEPT9-IN-1 (compound 8b) is a SEPT9 inhibitor with an IC50 value of 94.83 μM. SEPT9-IN-1 shows cytotoxicity to human oral squamous carcinomas with an IC50 value of 21 µM .
|
-
- HY-155785
-
|
|
Apoptosis
Autophagy
Reactive Oxygen Species (ROS)
JAK
|
Cancer
|
|
MTP is a PKM2 inhibitor. MTP induces cancer cell apoptosis by modulating caspase-3 activation. MTP induces autophagy and increases ROS generation. MTP also inhibits JAK2 signaling. MTP can be used for research of oral squamous cell carcinoma .
|
-
- HY-144254
-
|
|
PI3K
Akt
Apoptosis
|
Cancer
|
|
PI3Kδ-IN-10 is a highly potent and orally active PI3Kδ inhibitor with IC50 of 2 nM. PI3Kδ-IN-10 robustly suppresses the downstream AKT pathway to induce subsequent apoptosis in hepatocellular carcinoma models .
|
-
- HY-105854
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
JNK
p38 MAPK
MMP
|
Cancer
|
|
Pipoxolan hydrochloride is an anti-spasmotic agent. Pipoxolan hydrochloride induces Apoptosis, increases intracellular ROS. Pipoxolan hydrochloride down-regulates phosphorylation JNK and p38, and then, MMP-2 and -9. Pipoxolan hydrochloride relieves smooth muscle spasms in the digestive, urinary, and gynecological systems. Pipoxolan hydrochloride also exhibits anticancer activity against leukemia, oral squamous cell carcinoma, and lung adenocarcinoma .
|
-
- HY-101266A
-
|
DS-3032 tosylate
|
MDM-2/p53
|
Cancer
|
|
Milademetan tosylate is the tosylate salt form of Milademetan (HY-101266). Milademetan tosylate is an orally active inhibitor for MDM2. Milademetan tosylate arrests the cell cycle at G1 pahse, induces the apoptosis Milademetan tosylate restores the p53 activity by targeting the p53-MDM2 interaction, and exhibits anticancer activity against Merkel cell carcinoma (MCC) .
|
-
- HY-N8380
-
|
|
Apoptosis
Autophagy
PI3K
Necroptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .
|
-
- HY-19909A
-
|
|
EGFR
|
Cancer
|
|
NRC-2694-A is an orally effective EGFR tyrosine kinase inhibitor. NRC-2694-A can be used in the study of malignant squamous cell carcinoma (HNSCC) .
|
-
- HY-N12760
-
|
|
Others
|
Cancer
|
|
Lobophorin CR-2 is a lobophorin congener which induces UPR-associated gene expression, inhibits oral squamous cell carcinoma cell growth, and causes UPR-dependent cell death in MEF cells .
|
-
- HY-101840AR
-
|
L593754 hydrochloride (Standard); MH 12-43 hydrochloride (Standard); Ethylisopropylamiloride hydrochloride (Standard)
|
Reference Standards
TRP Channel
Autophagy
COX
Prostaglandin Receptor
Na+/H+ Exchanger (NHE)
|
Inflammation/Immunology
Cancer
|
|
EIPA (hydrochloride) (Standard) is the analytical standard of EIPA (hydrochloride). This product is intended for research and analytical applications. EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma .
|
-
- HY-W010593R
-
|
|
Drug Metabolite
Reference Standards
|
Cancer
|
|
Ethylenethiourea (Standard) is the analytical standard of Ethylenethiourea. This product is intended for research and analytical applications. Ethylenethiourea is a degradation product of the ethylenebisthiocarbamate group of fungicides. Ethylenethiourea is tumorigenic and teratogenic. Ethylenethiourea is orally active .
|
-
- HY-101840R
-
|
L593754 (Standard); MH 12-43 (Standard); Ethylisopropylamiloride (Standard)
|
Reference Standards
TRP Channel
Prostaglandin Receptor
Autophagy
COX
Na+/H+ Exchanger (NHE)
|
Inflammation/Immunology
Cancer
|
|
EIPA (Standard) is the analytical standard of EIPA. This product is intended for research and analytical applications. EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma .
|
-
- HY-168920
-
|
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
|
NSD-IN-4 (Compound A8) is a potent and an orally active NSD3 inhibitor. NSD-IN-4 induces Apoptosis in a dose-dependent manner. NSD-IN-4 exhibits significant antitumor effects against lung squamous carcinoma .
|
-
- HY-Y1155S
-
|
|
Isotope-Labeled Compounds
Biochemical Assay Reagents
Cytochrome P450
DNA Alkylator/Crosslinker
|
Inflammation/Immunology
Endocrinology
Cancer
|
|
Hexamethylphosphoramide-d18 is the deuterium labeled Hexamethylphosphoramide (HY-Y1155). Hexamethylphosphoramide is an orally active polar aprotic solvent, flame retardant additive, and carcinogen. Hexamethylphosphoramide undergoes cytochrome P-450-mediated N-demethylation to Formaldehyde. Hexamethylphosphoramide induces DNA-protein crosslinks. Hexamethylphosphoramide has been linked to nasal tumors (squamous cell carcinoma, adenoid squamous cell carcinoma), squamous metaplasia, rhinitis, tracheitis, and reversible and irreversible infertility .
|
-
- HY-163569
-
|
|
FGFR
|
Cancer
|
|
FGFR4-IN-20 (comp 11) is an orally active and selective FGFR4 inhibitor with IC50s of 19 and 36 nM against Huh7 cells and FGFR4 enzyme. FGFR4-IN-20 can be used for hepatocellular carcinoma research .
|
-
- HY-N3665
-
|
|
Tyrosinase
|
Cancer
|
|
Cyclocommunol is a prenylflavonoid with antityrosinase and antiplatelet activitie, can be solated from breadfruit. Cyclocommunol exerts anti-tumor activity and inhibits the growth of human hepatoma and gastric cancer cells with IC50 values between 16 and 80 µM. Cyclocommunol shows proapoptotic effect on oral squamous cell carcinoma (OSCC) .
|
-
- HY-112532A
-
|
|
Leukotriene Receptor
Lipoxygenase
|
Inflammation/Immunology
Cancer
|
|
REV 5901 hydrochloride is a competitive and orally active antagonist of leukotriene receptor, with a Ki of 0.7 μM. REV 5901 hydrochloride is also a 5-lipoxygenase inhibitor. REV 5901 hydrochloride can be used for the research of asthma in which leukotriene release be involved. REV 5901 hydrochloride can be used for the study of colon carcinoma .
|
-
- HY-13593S
-
|
CB-1348-d8; WR-139013-d8
|
Isotope-Labeled Compounds
DNA Alkylator/Crosslinker
|
Cancer
|
|
Chlorambucil-d8 is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .
|
-
- HY-13593S1
-
|
CB-1348-d8-1; WR-139013-d8-1
|
Isotope-Labeled Compounds
DNA Alkylator/Crosslinker
|
Cancer
|
|
Chlorambucil-d8-1 is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .
|
-
- HY-13593R
-
|
CB-1348 (Standard); WR-139013 (Standard)
|
Reference Standards
DNA Alkylator/Crosslinker
|
Cancer
|
|
Chlorambucil (Standard) is the analytical standard of Chlorambucil. This product is intended for research and analytical applications. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .
|
-
- HY-158762
-
|
|
SHP2
|
Cancer
|
|
TK-642 is a highly active, selective, orally activity SHP2 inhibitor based on pyrazole and pyrazine (IC50=2.7 nmol/L). TK-642 can effectively inhibit the proliferation of esophageal carcinoma cells and induce cell apoptosis. TK-642 can be used in the study of esophageal cancer .
|
-
- HY-N2414R
-
|
|
Reference Standards
Reactive Oxygen Species (ROS)
Necroptosis
Pyroptosis
Interleukin Related
Caspase
NOD-like Receptor (NLR)
|
Inflammation/Immunology
Cancer
|
|
Periplogenin (Standard) is the analytical standard of Periplogenin (HY-N2414). Periplogenin is an orally active cardiac glycoside found in Cortex periplocae. Periplogenin can induce ROS production and necroptosis and cause G0/G1 phase arrest. Periplogenin can inhibit pyroptosis by regulating the NLRP3/Caspase-1/GSDMD signaling. Periplogenin suppresses growth of prostate carcinoma cells by docking to an ATP1A1 protein pocket and forming a hydrogen bond with T804. Periplogenin can be used for the researches of cancer, inflammation and immunology, such as prostate carcinoma, rheumatoid arthritis and psoriasis .
|
-
- HY-106735R
-
|
Ro 13-6298 (Standard); Arotinoid ethyl ester (Standard)
|
Reference Standards
RAR/RXR
|
Inflammation/Immunology
Cancer
|
|
Arotinoid (Standard) (Ro 13-6298 (Standard)) is the analytical standard of Arotinoid (HY-106735). This product is intended for research and analytical applications. Arotinoid (RO 13-6298) is a retinoid, and acts as an orally active and highly potent agonist of retinoic acid receptors (RARs) with antipsoriatic effects. Arotinoid has antipapiltoma activity with an ED50 of 0.05 mg/kg. Arotinoid can be used for the research of sKin carcinomas .
|
-
- HY-180523
-
|
|
Pyruvate Kinase
Apoptosis
Reactive Oxygen Species (ROS)
Caspase
|
Cancer
|
|
PKM2-IN-13 is a selective PKM2 inhibitor inhibiting PKM2 with an IC50 value of 55.13 μM. PKM2-IN-13 exhibits broad-spectrum anticancer activity with low toxicity to normal cells. PKM2-IN-13 induces apoptosis by elevated ROS levels and activation of caspases 3/7, and interacts with and inhibits the glycolytic activity of Pyruvate Kinase M2 in virto. PKM2-IN-13 demonstrates a favorable safety profile with no significant adverse effects in vivo. PKM2-IN-13 can be used for oral squamous cell carcinoma (OSCC), colon carcinoma, breast cancer and melanoma research .
|
-
- HY-180805
-
|
|
Hexokinase
Mitophagy
Apoptosis
GLUT
|
Cancer
|
|
HK2-IN-3 (compound 12) is a potent hexokinase 2 (HK2) inhibitor with an IC50 of 56.4 nM. HK2-IN-3 reduces glucose uptake and downregulated GLUT1/GLUT4 in oral squamous cell carcinoma (OSCC). HK2-IN-3 induces mitophagy and apoptosis. HK2-IN-3 suppresses tumor growth and angiogenesis in OSCC xenograft mouse models. HK2-IN-3 can be used for OSCC research .
|
-
- HY-N17854
-
|
|
Drug Derivative
|
Others
|
|
3β-O-α-L-Arabinopyranosylsiaresinolic acid 28-O-β-D-glucopyranosyl ester is a triterpene glycoside found in the roots of Sanguisorba officinalis. 3β-O-α-L-Arabinopyranosylsiaresinolic acid 28-O-β-D-glucopyranosyl ester is non-cytotoxic and does not exhibit cytotoxic activity against human oral squamous cell carcinoma cells or normal human gingival fibroblasts .
|
-
- HY-106364A
-
|
Bleomycin PEP sulfate; Pepleomycin sulfate
|
Apoptosis
Antibiotic
|
Infection
Cancer
|
|
Peplomycin (Bleomycin PEP) sulfate is an analog of Bleomycin (HY-108345) and an antitumor antibiotic. Peplomycin sulfate exhibits potent antitumor activity and relatively low pulmonary toxicity. Peplomycin sulfate can induce various skin abnormalities and trigger apoptosis in SSCKN cells of oral squamous cell carcinoma. Peplomycin sulfate can also induce pulmonary fibrosis. Peplomycin sulfate is applicable for the research of tumors, pulmonary fibrosis and other related diseases .
|
-
- HY-135146G
-
|
|
DNA Methyltransferase
Apoptosis
|
Cancer
|
|
GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma .
|
-
- HY-112385
-
|
|
SphK
PERK
|
Cancer
|
|
ABC294735 is an orally active SK1/SK2 inhibitor. Combination of ABC294735 with Sorafenib (HY-10201) reduces pERK. ABC294735 exhibits anticancer activity against pancreatic adenocarcinoma and renal cell carcinoma. ABC294735 can be used in research related to pancreatic adenocarcinoma and renal cell carcinoma .
|
-
- HY-183078
-
|
|
Deubiquitinase
|
Cancer
|
|
P6620 is an orally active USP7 inhibitor. P6620 specifically binds to USP7 and disrupts its interaction with LRRC41. P6620 exhibits anticancer activity against hepatocellular carcinoma. P6620 enhances the antitumor effect of Lenvatinib (HY-10981) in xenograft mouse models. P6620 can be used for the research of hepatocellular carcinoma .
|
-
- HY-105854A
-
|
|
Ras
MEK
ERK
PI3K
Akt
MMP
Keap1-Nrf2
Heme Oxygenase (HO)
Reactive Oxygen Species (ROS)
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Pipoxolan is an orally active smooth muscle relaxant, anti-inflammatory agent and anticancer agent. Pipoxolan modulates PI3K/AKT signaling pathways, and reduces the levels of Ras/MEK/p-ERK, MMP-2 and MMP-9. Pipoxolan inhibits pro-inflammatory transcription factor pathways, activates Nrf2/HO-1, and suppresses the production of pro-inflammatory mediators. Pipoxolan induces ROS generation, endogenous mitochondrial Apoptosis, and G0/G1 cell cycle arrest. Pipoxolan reduces cerebral infarction size and inhibits intimal hyperplasia. Pipoxolan can be used in research related to cerebral ischemia, intimal hyperplasia, oral squamous cell carcinoma, leukemia and lung cancer .
|
-
- HY-133151
-
|
|
CXCR
|
Cancer
|
|
CXCR6 antagonist 1 (Compound 81) is an orally active CXCR6 antagonist. CXCR6 antagonist 1 inhibits the CXCR6 receptor signaling pathway, including β-arrestin recruitment and Forskolin (HY-15371)-induced cAMP production. CXCR6 antagonist 1 reduces tumor growth in a mouse xenograft model of hepatocellular carcinoma. CXCR6 antagonist 1 can be used in research related to hepatocellular carcinoma .
|
-
- HY-106797
-
|
|
SOD
Xanthine Oxidase
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
CV 3611 is a potent and orally active free radical scavenger. CV 3611 shows anti-inflammatory, antiarrhythmic and anticancer effects. CV 3611 can be used for the researches of cancer, inflammation and cardiovascular disease, such as hepatocellular carcinoma and acute pancreatitis .
|
-
- HY-N18150
-
|
|
Others
|
Cancer
|
|
12-O-Methylvolkensin is a limonoid found in the fruits of Melia toosendan Sieb. et Zucc. 12-O-Methylvolkensin shows cytotoxicity against cancer cells. 12-O-Methylvolkensin can be used for the research of cancer, such as human oral epidermoid carcinoma .
|
-
- HY-19272
-
|
|
Nucleoside Antimetabolite/Analog
Asialoglycoprotein Receptor (ASGPR)
|
Cancer
|
|
OGT-719 is a potent, orally active nucleoside analogue that targets the asialoglycoprotein receptor (ASGP-R). OGT-719 inhibits growth of metastatic colorectal tumors in the liver of nude mice. OGT-719 can be used for primary hepatocellular carcinoma and colorectal liver metastases research .
|
-
- HY-106919
-
-
- HY-181712
-
|
|
IRAK
|
Cancer
|
|
IRAK1-IN-2 is an orally active IRAK1 inhibitor and antitumor agent with high selectivity for IRAK4 and other kinases in the same group. IRAK1-IN-2 functionally inhibits IRAK1 and interferes with the TLR/IL-1R signaling pathway. IRAK1-IN-2 suppresses hepatocellular carcinoma-related cellular processes in vitro and in animal models. IRAK1-IN-2 serves as a chemical probe for IRAK1 research and is applicable to studies on hepatocellular carcinoma .
|
-
- HY-181793
-
|
|
VEGFR
HDAC
Microtubule/Tubulin
|
Cancer
|
|
VEGFR2/HDAC-IN-1 is a dual selective enzymatic inhibitor of VEGFR2 kinase and HDAC6 with oral activity. VEGFR2/HDAC-IN-1 has an IC50 of 19.19 nM for VEGFR2 and 0.165 μM for HDAC6. VEGFR2/HDAC-IN-1 increases α-tubulin acetylation, exerts antiproliferative effects, inhibits tumor growth, and exhibits antiangiogenic activity. VEGFR2/HDAC-IN-1 can be used for the research of colorectal carcinoma and hepatocellular carcinoma .
|
-
- HY-183117
-
|
|
Molecular Glues
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
NEO-811 is a selective and orally active ARNT (HIF-1β) molecular glue degrader. NEO-811 is mediated by CRL4-CRBN E3 ligase for ARNT degradation. NEO-811 can be used for the study of clear cell renal cell carcinoma (ccRCC) .
|
-
- HY-17493A
-
|
|
MDM-2/p53
Apoptosis
|
Neurological Disease
Cancer
|
|
MI-773 TFA is an orally active, selective MDM2-p53 interaction inhibitor with a Ki of 0.88 nM for MDM2. MI-773 TFA blocks the MDM2-TP53 interaction. MI-773 TFA potently activates p53. MI-773 TFA induces Apoptosis. MI-773 TFA causes tumor regression in xenograft models of adenoid cystic carcinoma. MI-773 TFA exhibits anticancer effects in neuroblastoma. MI-773 TFA can be used for the research of adenoid cystic carcinoma .
|
-
- HY-182915
-
|
|
FGFR
|
Cancer
|
|
FGFR-IN-26 is an orally active FGFR inhibitor. FGFR-IN-26 inhibits FGFR2 wild-type and clinically relevant resistance mutations. FGFR-IN-26 inhibits tumor growth in FGFR2-amplified xenograft mouse models. FGFR-IN-26 can be used for the research of cancer, suah as gastric carcinoma .
|
-
- HY-N19845
-
|
|
Drug Derivative
|
Neurological Disease
Cancer
|
|
2′,7-Diacetyltaxol (Compound 3) is an acetylated derivative of Paclitaxel (HY-B0015) and a cytotoxic agent. 2′,7-Diacetyltaxol is isolated from the acetylated fraction of Taxus brevifolia Nutt. 2′,7-Diacetyltaxol exhibits anticancer activity against oral epidermoid carcinoma. 2′,7-Diacetyltaxol is applicable to the research of neurological diseases .
|
-
- HY-100491
-
|
|
FGFR
|
Cancer
|
|
H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity .
|
-
- HY-100491R
-
|
|
FGFR
Reference Standards
|
Cancer
|
|
H3B-6527 (Standard) is the analytical standard of H3B-6527 (HY-100491). This product is intended for research and analytical applications. H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity .
|
-
- HY-114906
-
|
|
Sirtuin
|
Cancer
|
|
SIRT1/2/3-IN-2 (compound 9) is a potent SIRT inhibitor, with inhibition rates of 27%, 72%, and 71% targeting SIRT1, SIRT2, and SIRT3, respectively, at 200 μM. SIRT3 is a potential tumor suppressor or promoter, and its increased transcription may be associated with lymph node-positive breast cancer and oral squamous cell carcinoma .
|
-
- HY-135644
-
|
CRV431
|
Cyclophilin
Sirtuin
Nuclear Factor of activated T Cells (NFAT)
Interleukin Related
|
Cancer
|
|
Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC50 values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease .
|
-
- HY-103706R
-
|
|
Reference Standards
Autophagy
Apoptosis
|
Cancer
|
|
ROC-325 (Standard) is the analytical standard of ROC-325 (HY-103706). This product is intended for research and analytical applications. ROC-325 is a potent and orally active autophagy inhibitor with a strong anticancer activity. ROC-325 induces the deacidification of lysosomes, accumulation of autophagosomes, and disrupted autophagic flux. ROC-325 also induces renal cell carcinoma apoptosis .
|
-
- HY-16706A
-
|
|
Histone Acetyltransferase
|
Cancer
|
|
Remodelin hydrobromide is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin hydrobromide inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin hydrobromide inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin hydrobromide enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model .
|
-
- HY-135562
-
|
|
Parasite
Antibiotic
|
Infection
Cancer
|
|
Ascofuranone is an orally active inhibitor of Trypanosoma brucei brucei (TAO) with a Ki value of 2.38 nM. Ascofuranone inhibits IGF-1-induced cancer cell migration, invasion, motility and actin cytoskeleton formation, and exerts anti-tumor effects. Ascofuranone can be used in research related to tumor metastasis, African trypanosomiasis, bacterial infections, lung cancer and hepatocellular carcinoma .
|
-
- HY-125840R
-
|
PT2977 (Standard); MK-6482 (Standard)
|
HIF/HIF Prolyl-Hydroxylase
Reference Standards
|
Cancer
|
|
Belzutifan (Standard) is the analytical standard of Belzutifan. This product is intended for research and analytical applications. Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .
|
-
- HY-N11764
-
|
|
Apoptosis
Caspase
|
Cancer
|
|
β-Santalol is a sesquiterpene alcohol with apoptosis (apoptosis)-inducing activity and cytotoxic activity. β-Santalol activates caspase-3, induces nuclear chromatin condensation, and promotes the formation of apoptotic bodies. β-Santalol targets cancer cells. β-Santalol can be used in research related to promyelocytic leukemia, lung adenocarcinoma, and oral squamous cell carcinoma .
|
-
- HY-13787
-
|
|
Akt
Ribosomal S6 Kinase (RSK)
GSK-3
|
Cancer
|
|
XL-418 is an orally active dual Akt and p70S6K inhibitor with IC50s of 1 nM for Akt1 and 2 nM for p70S6K. XL-418 inhibits the phosphorylation of ribosomal protein S6 and GSK3β. XL-418 can be used for the study of prostate carcinoma and breast cancer .
|
-
- HY-50767D
-
|
PD 0332991 orotate
|
CDK
|
Cancer
|
|
Palbociclib (PD 0332991) orotate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib orotate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib orotate can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
|
-
- HY-50767A
-
|
PD 0332991 monohydrochloride
|
CDK
|
Cancer
|
|
Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
|
-
- HY-100492R
-
|
BLU-554 (Standard)
|
FGFR
Reference Standards
|
Cancer
|
|
Fisogatinib (Standard) is the analytical standard of Fisogatinib (HY-100492). This product is intended for research and analytical applications. Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling .
|
-
- HY-A0065
-
|
PD 0332991 isethionate
|
CDK
|
Infection
Neurological Disease
Cancer
|
|
Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
|
-
- HY-159642G
-
|
TYRA-300
|
FGFR
ERK
|
Metabolic Disease
Cancer
|
|
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
|
-
- HY-162616
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
SelSA is a selective, orally active inhibitor for histone deacetylase 6 (HDAC6) with IC50 of 56.9 nM. SelSA inhibits the phosphorylation of ERK1/2. SelSA inhibits the proliferation of breast cancer cells and hepatocellular carcinoma cells with IC50 of 0.58-2.6 μM, inhibits cell migration and invasion of Huh7, and induces apoptosis. SelSA exhibits antitumor activity in mouse model .
|
-
- HY-B0023
-
|
CS 905
|
Calcium Channel
MEK
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Azelnidipine (CS 905) is a dihydropyridine calcium channel blocker that is effective orally. Azelnidipine inhibits the intracellular calcium ion flow and lower blood pressure by selectively blocking L-type calcium channel on the membrane of vascular smooth muscle. Azelnidipine inhibits esophageal squamous cell carcinoma proliferation by targeting MEK1/2. Azelnidipine also has anti-inflammatory, antioxidant and neuroprotective effects .
|
-
- HY-N0864
-
|
Macranthoiside I
|
Apoptosis
COX
Reactive Oxygen Species (ROS)
Caspase
SOD
|
Cancer
|
|
Macranthoidin B (Macranthoiside I) is an orally active triterpene saponin. Macranthoidin B inhibits epithelial-mesenchymal transition in endometriosis via the COX‑2/PGE2 pathway, and also induces tumor cell apoptosis and inhibits their proliferation by regulating metabolism and increasing ROS levels . Macranthoidin B can be used in studies related to endometriosis, colorectal cancer and hepatocellular carcinoma .
|
-
- HY-165245
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .
|
-
- HY-N18294
-
|
|
Parasite
|
Infection
Cancer
|
|
(R,R)-Polysphorin is a neolignan antimalarial agent that is isolated from the dried leaves and stems of Rhaphidophora decursiva. (R,R)-Polysphorin inhibits the growth of chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum clones in vitro by mediating free radical damage to key cellular components via conjugated double bonds. (R,R)-Polysphorin also exhibits cytotoxicity against human oral epidermoid carcinoma cells .
|
-
- HY-10977R
-
|
AV-951 (Standard); KRN951 (Standard)
|
VEGFR
Reference Standards
|
Cancer
|
|
Tivozanib (Standard) is the analytical standard of Tivozanib. This product is intended for research and analytical applications. Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy .
|
-
- HY-10977
-
|
AV-951; KRN951
|
VEGFR
|
Cancer
|
|
Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy .
|
-
- HY-10977A
-
|
AV-951 hydrochloride hydrate; KRN951 hydrochloride hydrate
|
VEGFR
|
Cancer
|
|
Tivozanib hydrochloride hydrate is the hydrate hydrochloride form of Tivozanib (HY-10977). Tivozanib hydrochloride hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrochloride hydrate exhibits antitumor efficacy .
|
-
- HY-10977AR
-
|
AV-951 hydrochloride hydrate (Standard); KRN951 hydrochloride hydrate (Standard)
|
VEGFR
Reference Standards
|
Cancer
|
|
Tivozanib (hydrochloride hydrate) (Standard) is the analytical standard of Tivozanib (hydrochloride hydrate). This product is intended for research and analytical applications. Tivozanib hydrochloride hydrate is the hydrate hydrochloride form of Tivozanib (HY-10977). Tivozanib hydrochloride hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrochloride hydrate exhibits antitumor efficacy .
|
-
- HY-178098
-
|
|
YAP
|
Cancer
|
|
TEAD-IN-21 is a potent and orally active pan-TEAD inhibitor with an IC50 of 3 nM. TEAD-IN-21 effectively inhibited the proliferation of Huh-7 cells. TEAD-IN-21 selectively downregulates TEAD-dependent downstream genes. TEAD-IN-21 achieves tumor regression in a liver cancer-derived tumor xenograft mice model. TEAD-IN-21 can be used in the research of hepatocellular carcinoma (HCC) .
|
-
- HY-103018
-
|
ASN-002
|
JAK
Syk
|
Inflammation/Immunology
Cancer
|
|
Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
|
-
- HY-106219
-
|
|
Microtubule/Tubulin
P-glycoprotein
|
Cancer
|
|
BMS 275183 is a potent, orally active analogue of Paclitaxel (HY-B0015). BMS 275183 can stabilize microtubules and exhibits antitumor activity in in vivo tumor models. BMS 275183 is active in vitro against Paclitaxel-resistant tumors including those harboring tubulin mutations or overexpressing P-glycoprotein. BMS 275183 can be used for cancer research, such as non-small cell lung cancer (NSCLC) and prostate carcinoma .
|
-
- HY-103018A
-
|
ASN-002 hydrochloride
|
JAK
Syk
|
Inflammation/Immunology
Cancer
|
|
Gusacitinib (ASN-002) hydrochloride is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib hydrochloride rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib hydrochloride can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
|
-
- HY-W654305
-
|
PD 0332991-d4
|
Isotope-Labeled Compounds
CDK
|
Cancer
|
|
Palbociclib-d4 is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
|
-
- HY-13752
-
|
|
HSP
|
Cancer
|
|
STA-1474 is an orally active and highly selective HSP90 inhibitor. STA-1474 can trigger tumor cell apoptosis. STA-1474 demonstrates significant antitumor efficacy in spontaneous canine cancer models (e.g., osteosarcoma, thyroid carcinoma). STA-1474 is promising for research of solid tumors (e.g., osteosarcoma, breast cancer) and HSP90-driven cancers .
|
-
- HY-119906
-
|
FW-04-806
|
HSP
Apoptosis
|
Cancer
|
|
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .
|
-
- HY-183539
-
|
|
DGK
Interleukin Related
|
Cancer
|
|
INCB191358 is a selective and orally active inhibitor of diacylglycerol kinase α/ζ/ι (DGKα/ζ/ι ) with IC50 values of 0.12, 0.36 and 0.36 nM. INCB191358 induces antigen-dependent T-cell activation, induces IL-2 production and enhances antitumor efficacy in combination with PD-1 blockade. INCB191358 can be used for the research of cancer, such as colon carcinoma .
|
-
- HY-180897
-
|
|
Ribosomal S6 Kinase (RSK)
|
Cancer
|
|
RSK4-IN-2 (compound 16o) is a potent, orally active RSK4 inhibitor with an IC50 of 17 nM. RSK4-IN-2 suppresses esophageal squamous cell carcinoma (ESCC) cell growth and invasion, by inhibiting phosphorylation of RSK4 downstream targets. RSK4-IN-2 inhibits tumor growth and metastasis in ESCC mouse models. RSK4-IN-2 can be used for ESCC research .
|
-
- HY-17473
-
Embelin
Maximum Cited Publications
6 Publications Verification
Embelic acid; Emberine; NSC 91874
|
IAP
NF-κB
Apoptosis
Autophagy
|
Cancer
|
|
Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC50=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .
|
-
- HY-159644
-
|
AB521
|
HIF/HIF Prolyl-Hydroxylase
VEGFR
|
Cancer
|
|
Casdatifan (AB521) is an orally active and selective allosteric small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α). Casdatifan inhibits pro-tumor gene transcription by blocking the heterodimerization of HIF-2α with ARNT, and significantly suppresses tumor growth in clear cell renal cell carcinoma (ccRCC) models either as a monotherapy or in combination with agents such as Zimberelimab (HY-P99109). Casdatifan is applicable for the research of ccRCC .
|
-
- HY-147203
-
|
|
5-HT Receptor
|
Cardiovascular Disease
Metabolic Disease
Endocrinology
Cancer
|
|
5-HT2B antagonist-1 is an orally active 5-HT2B receptor antagonist with an IC50 value of 33.4 nM. 5-HT2B antagonist-1 can be used in studies of diseases characterized by 5-HT2B receptor signaling, such as hepatocellular carcinoma, cardiovascular disease or gastrointestinal disease .
|
-
- HY-182506
-
|
BM 12.531
|
Biochemical Assay Reagents
|
Inflammation/Immunology
Cancer
|
|
Azimexon (BM 12.531) is an orally active immunomodulator with radioprotective and antitumor activities. Azimexon prolongs survival in multiple mouse models, enhances immunity and hematopoiesis, and alleviates radiation injury and tumor metastasis. Azimexon causes reversible hemolytic anemia in rats and dogs, and exerts therapeutic activity against adjuvant-induced arthritis in rats. Azimexon can be used for the research of lung carcinoma, leukemia, multiple myeloma, lung tumor, arthritis, breast cancer and AIDS‑related complex .
|
-
- HY-178140
-
|
|
STAT
|
Cancer
|
|
STAT3-IN-47 is an orally active STAT3 inhibitor. STAT3-IN-47 exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells. STAT3-IN-47 suppresses STAT3 activation in vitro. STAT3-IN-47 can be used for the study of solid tumors, especially central nervous system (CNS) malignancies and hepatocellular carcinoma .
|
-
- HY-110088
-
|
|
MDM-2/p53
|
Cancer
|
|
SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a Ki of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .
|
-
- HY-183639
-
|
|
Succinate Receptor 1
Apoptosis
|
Cancer
|
|
SUCNR1 antagonist-1 is an orally active SUCNR1 antagonist. SUCNR1 antagonist-1 forms stable, water-bridged hydrogen bonds with key residue Glu22 1.31 to stabilize binding conformation and modulates protein conformational flexibility. SUCNR1 antagonist-1 blocks succinate-mediated SUCNR1 signaling and induces cell apoptosis. SUCNR1 antagonist-1 can be used for the research of colorectal carcinoma .
|
-
- HY-172874
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
TDO-IN-2 (Compound 5c) is an orally active TDO inhibitor (IC50: 1.25 μM). TDO-IN-2 has antitumor activity in the Hepa1-6 hepatocellular carcinoma allograft mouse model. TDO-IN-2 has synergistic effects with the PD-1/PD-L1 inhibitor BMS-202 (HY-19745) and can be used to study tumor immune tolerance .
|
-
- HY-50767R
-
|
PD 0332991 (Standard)
|
Reference Standards
CDK
|
Cancer
|
|
Palbociclib (Standard) is the analytical standard of Palbociclib. This product is intended for research and analytical applications. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
|
-
- HY-N2115
-
|
Chikusetsusaponin IV
|
Renin
Apoptosis
Bcl-2 Family
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Araloside A (Chikusetsusaponin IV), triterpenoid saponins, is an orally active component of Aralia elata. Araloside A shows low-renin-inhibitory activity with an IC50 of 77.4 μM. Araloside A can inhibit cell proliferation and induce apoptosis. Araloside A suppresses inflammatory cytokines IL-1β and IL-6 production. Araloside A can be used for the researches of cancer, inflammation and cardiovascular disease, such as renal cell carcinoma and rheumatoid arthritis .
|
-
- HY-N0885
-
|
Telobufotoxin; Telocinobufogenin
|
JAK
STAT
mTOR
PI3K
Akt
Polo-like Kinase (PLK)
Na+/K+ ATPase
Apoptosis
Bacterial
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na +/K +-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models .
|
-
- HY-119272
-
EF24
2 Publications Verification
|
ERK
Caspase
NF-κB
Apoptosis
p38 MAPK
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
Cancer
|
|
EF24, a curcumin analogue, is an NF-kB inhibitor with great anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 is active against melanoma and breast cancer cell lines with GI50 values of 0.7 μM and 0.8 μM, respectively. EF24 induces cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. EF24 increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK .
|
-
- HY-W998347
-
|
|
Molecular Glues
NEKs
|
Cancer
|
|
ABS-752 is an orally active prodrug of CRBN-modulating molecular glue targeting. ABS-752 can effectively degrade GSPT1. ABS-752 can degrade NEK7. ABS-752 does not form ternary complexes with CRBN and the neosubstrates. ABS-752 is a prodrug activated by the monoamine oxidase, VAP-1, to an aldehyde intermediate and subsequently to the active molecule, ABT-002. ABS-752 can be used for the study of hepatocellular carcinoma (HCC) .
|
-
- HY-122214
-
|
|
Autophagy
|
Cancer
|
|
AC-73 is a first specific, orally active inhibitor of cluster of differentiation 147 (CD147), which specifically disrupts CD147 dimerization, thereby mainly suppressing the CD147/ERK1/2/STAT3/MMP-2 pathways. AC-73 inhibits the motility and invasion of hepatocellular carcinoma cells . AC-73 is also an anti-proliferative agent and an inducer of autophagy in leukemic cells .
|
-
- HY-137978A
-
|
GNS561 hydrochloride
|
SARS-CoV
IFNAR
Autophagy
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Ezurpimtrostat hydrochloride (GNS561 hydrochloride) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat hydrochloride inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat hydrochloride reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat hydrochloride can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .
|
-
- HY-N6726R
-
|
|
Reference Standards
Fungal
Endogenous Metabolite
|
Infection
Cancer
|
|
Fumonisin B3 (Standard) is the analytical standard of Fumonisin B3. This product is intended for research and analytical applications. Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
|
-
- HY-N6726S
-
|
|
Isotope-Labeled Compounds
Fungal
Endogenous Metabolite
|
Infection
Cancer
|
|
Fumonisin B3- 13C34 is the 13C labeled Fumonisin B3 (HY-N6726). Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
|
-
- HY-114178
-
|
|
CDK
STAT
Wnt
5-HT Receptor
PASK/STK37
|
Cancer
|
|
CDK8-IN-2 is an orally active CDK8 inhibitor of an IC50 values of 0.010 μM. CDK8-IN-2 shows a CDK19 IC50 value of 0.026 μM. CDK8-IN-2 inhibits phospho-STAT1, a pharmacodynamic biomarker of CDK8. CDK8-IN-2 inhibits WNT pathway activity. CDK8-IN-2 can be used for the research of colorectal carcinoma .
|
-
- HY-13902
-
|
VE-822; VX-970; M6620
|
ATM/ATR
Apoptosis
STING
Caspase
|
Infection
Metabolic Disease
Cancer
|
|
Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .
|
-
- HY-169766
-
|
|
Molecular Glues
Keap1-Nrf2
|
Cancer
|
|
VVD 065 is an orally active KEAP1-dependent NRF2 molecular glue degrader with a KEAP1 KD of 65 nM. VVD 065 covalently engages KEAP1 at Cys151, allosterically stabilizes KEAP1-CUL3 complex formation and enhances NRF2 polyubiquitination and proteasomal degradation. VVD 065 can be used for the research of esophageal squamous cell carcinoma, lung cancer, head-and-neck cancer, uterine cancers .
|
-
- HY-174275
-
|
|
YAP
|
Inflammation/Immunology
Cancer
|
|
TEAD1/3/4-IN-1 is an orally active inhibitor of TEAD1/3/4. TEAD1/3/4-IN-1 inhibits the YAP/TAZ-TEAD interaction, with its EC50 being 2 nM. TEAD1/3/4-IN-1 has anti-proliferative activity against NCI-H226 cells. TEAD1/3/4-IN-1 can be used in the research of lung squamous cell carcinoma .
|
-
- HY-16191
-
|
|
Microtubule/Tubulin
Apoptosis
HIF/HIF Prolyl-Hydroxylase
Mitosis
|
Cancer
|
|
ELR510444 is an orally active tubulin inhibitor with an IC50 of 10 μM. ELR510444 binds to the colchicine-binding site on β-tubulin, inhibits tubulin assembly, depolymerizes microtubules and blocks HIF activity. ELR510444 induces cellular microtubule loss, abnormal mitotic spindle, mitotic arrest, apoptosis, morphological changes in tumor endothelial cells, and inhibits cancer cell proliferation, angiogenesis and tumor growth. ELR510444 can be used in research related to various cancers such as renal cell carcinoma .
|
-
- HY-50767AR
-
|
PD 0332991 monohydrochloride (Standard)
|
CDK
Reference Standards
|
Cancer
|
|
Palbociclib (monohydrochloride) (Standard) is the analytical standard of Palbociclib (monohydrochloride). This product is intended for research and analytical applications. Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
|
-
- HY-137978
-
|
GNS561
|
SARS-CoV
IFNAR
Autophagy
Apoptosis
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .
|
-
- HY-162679
-
|
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
c-Met degrader-1 (Compound H11) is an orally active c-Met degrader (through the ubiquitin proteasome system). c-Met degrader-1 has anti-hepatocellular carcinoma activity (HCC) and inhibits tumor growth in MHCC97H xenografts. c-Met degrader-1 inhibits HCC cell growth, arrests cell cycle, and induces apoptosis. c-Met degrader-1 may overcome resistance to type Ib inhibitors .
|
-
- HY-13902A
-
|
VE-822 hydrochloride; VX-970 hydrochloride; M6620 hydrochloride
|
ATM/ATR
Apoptosis
STING
Caspase
|
Neurological Disease
Cancer
|
|
Berzosertib (VE-822) hydrochloride is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib hydrochloride blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib hydrochloride induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib hydrochloride can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .
|
-
- HY-181667
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
Enpp-1-IN-30 (compound 44a) is an orally active ENPP1 inhibitor with a human IC50 of 13.1 nM. Enpp-1-IN-30 prevents cGAMP degradation, activates the STING pathway. Enpp-1-IN-30 induces cytokine release to enhance innate immune response. Enpp-1-IN-30 exerts antitumor efficacy in syngeneic mouse models. Enpp-1-IN-30 can be used for the research of colon carcinoma .
|
-
- HY-N2115R
-
|
Chikusetsusaponin IV (Standard)
|
Reference Standards
Renin
Apoptosis
Bcl-2 Family
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Araloside A (Standard) (Chikusetsusaponin IV (Standard)), triterpenoid saponins, is an orally active component of Aralia elata. Araloside A (Standard) shows low-renin-inhibitory activity with an IC50 of 77.4 μM. Araloside A (Standard) can inhibit cell proliferation and induce apoptosis. Araloside A (Standard) suppresses inflammatory cytokines IL-1β and IL-6 production. Araloside A (Standard) can be used for the researches of cancer, inflammation and cardiovascular disease, such as renal cell carcinoma and rheumatoid arthritis .
|
-
- HY-120115
-
|
Olaparib-bodipy FL
|
PARP
Fluorescent Dye
|
Cancer
|
|
PARPi-FL (Olaparib-bodipy FL) is a small-molecule fluorescent inhibitor of PARP1 that can specifically bind to PARP1. PARPi-FL can be used as a fluorescent imaging agent for tumor detection, diagnosis, and surgical guidance .
|
-
- HY-103018R
-
|
ASN-002 (Standard)
|
Reference Standards
JAK
Syk
|
Inflammation/Immunology
Cancer
|
|
Gusacitinib (Standard) is the analytical standard of Gusacitinib (HY-103018). This product is intended for research and analytical applications. Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
|
-
- HY-183780
-
|
|
FGFR
Akt
PERK
Apoptosis
Ferroptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
FGFR-IN-27 is an orally active, broad-spectrum FGFR inhibitor, with an IC50 of 0.24 nM against human FGFR1, 0.71 nM against FGFR2, 0.87 nM against FGFR3, and 6.50 nM against FGFR4. FGFR-IN-27 inhibits cancer cell proliferation and blocks tumor growth. FGFR-IN-27 reduces the phosphorylation levels of AKT and ERK, induces apoptosis and ferroptosis, increases ROS levels, and decreases GSH levels. FGFR-IN-27 can be used in the research of hepatocellular carcinoma .
|
-
- HY-10226
-
|
R306465
|
Apoptosis
HDAC
|
Cancer
|
|
JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases
the expression of p21 waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .
|
-
- HY-10261A
-
|
BIBW 2992MA2
|
EGFR
Autophagy
Apoptosis
c-Met/HGFR
Akt
p38 MAPK
|
Cancer
|
|
Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
|
-
- HY-117286
-
|
TEN-010
|
Epigenetic Reader Domain
Apoptosis
|
Neurological Disease
Cancer
|
|
(S)-JQ-35 (TEN-010) is an orally active, blood-brain barrier-permeable bromodomain inhibitor that selectively targets the bromodomain and extra-terminal domain (BET) protein family (BRD4, BRD3, BRD2 and BRDT). (S)-JQ-35 blocks the activation of Myc gene expression by BRD4, thereby inhibiting cancer cell proliferation and promoting cancer cell apoptosis. (S)-JQ-35 can be used in research related to NUT midline carcinoma and neuroblastoma .
|
-
- HY-109569
-
|
|
Autophagy
Apoptosis
Interleukin Related
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Vitamin K2 is an orally active proliferation inhibitor. Vitamin K2 induces Autophagy and Apoptosis. Vitamin K2 reduces the levels of proinflammatory cytokines (such as IL-1β, TNF-α, and IL-6). Vitamin K2 inhibits cell growth in leukemia cells. Vitamin K2 can be used for the research of involutional osteoporosis, non-alcoholic fatty liver disease, ulcerative colitis, acute myeloid leukemia, myelodysplastic syndromes, and hepatocellular carcinoma .
|
-
- HY-N2217
-
-
- HY-175606
-
|
|
ATP Citrate Lyase
|
Cancer
|
|
EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor. EVT0185 is converted to a CoA thioester in the liver by SLC27A2 and interacts with the CoA-binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC50 of 2.5 μM. EVT0185 can phenocopy the immune and antitumour effects of genetic ACLY deletion. EVT0185 can increase tumour-infiltrating B cells and chemokine CXCL13 levels. EVT0185 can be used for the research of cancer, such as hepatocellular carcinoma (HCC) .
|
-
- HY-10261
-
|
BIBW 2992
|
EGFR
Autophagy
Apoptosis
c-Met/HGFR
Akt
p38 MAPK
|
Cancer
|
|
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
|
-
- HY-147066
-
|
|
DYRK
|
Cancer
|
|
Dyrk1A-IN-4 is a potent and orally active Dyrk1A inhibitor. Dyrk1A-IN-4 exhibits IC50s against DYRK1A and DYRK2 of 2 nM and 6 nM. Dyrk1A-IN-4 exhibits the inhibition of the DYRK1A pSer520 autophosphorylation in U2OS cells with an IC50 of 28 nM. Dyrk1A-IN-4 can be used for the studies of ovarian adenocarcinoma, neuroblastoma and cervical squamous cell carcinoma .
|
-
- HY-10261D
-
|
BIBW 2992 oxalate
|
EGFR
Autophagy
Apoptosis
c-Met/HGFR
Akt
|
Cancer
|
|
Afatinib (BIBW 2992) oxalate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib oxalate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
|
-
- HY-W286743
-
|
CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine
|
Polo-like Kinase (PLK)
ERK
NF-κB
|
Cancer
|
|
Nε-(Carboxymethyl)-L-lysine (CML) is an orally active advanced glycation end product. Nε-(Carboxymethyl)-L-lysine upregulates the expression of PLK1 and CEP20, and induces the activation of RAGE and ERK/NFκB. Nε-(Carboxymethyl)-L-lysine drives centrosome amplification. Nε-(Carboxymethyl)-L-lysine induces malignant transformation of hepatocytes and promotes the development of hepatocellular carcinoma. Nε-(Carboxymethyl)-L-lysine induces epithelial-mesenchymal transition in osteosarcoma cells and enhances their migration and invasion properties .
|
-
- HY-N6726S1
-
|
|
Isotope-Labeled Compounds
Fungal
Endogenous Metabolite
|
Infection
Cancer
|
|
Fumonisin B3-13C34-1 is the isotopic internal standard of Fumonisin B3 (HY-N6726). Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
|
-
- HY-N0864R
-
|
Macranthoiside I (Standard)
|
Reference Standards
Others
|
Cancer
|
|
Macranthoidin B (Macranthoiside I) Standard is the analytical standard of Macranthoidin B (HY-N0864). This product is intended for research and analytical applications. Macranthoidin B (Macranthoiside I) is an orally active triterpene saponin. Macranthoidin B inhibits epithelial-mesenchymal transition in endometriosis via the COX‑2/PGE2 pathway, and also induces tumor cell apoptosis and inhibits their proliferation by regulating metabolism and increasing ROS levels . Macranthoidin B can be used in studies related to endometriosis, colorectal cancer and hepatocellular carcinoma .
|
-
- HY-103018S
-
|
ASN-002-d4
|
Isotope-Labeled Compounds
JAK
Syk
|
Inflammation/Immunology
Cancer
|
|
Gusacitinib-d4 (ASN-002-d4) is the deuterium labeled Gusacitinib (HY-103018). Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
|
-
- HY-100008
-
|
NIK333
|
RAR/RXR
SphK
Autophagy
HCV
|
Infection
Cancer
|
|
Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1 . Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression . Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC50 of 9 μM .
|
-
- HY-17473R
-
|
Embelic acid (Standard); Emberine (Standard); NSC 91874 (Standard)
|
Reference Standards
IAP
NF-κB
Apoptosis
Autophagy
|
Cancer
|
|
Embelin (Standard) is the analytical standard of Embelin. This product is intended for research and analytical applications. Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC50=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .
|
-
- HY-10261R
-
|
BIBW 2992 (Standard)
|
Reference Standards
EGFR
Autophagy
Apoptosis
c-Met/HGFR
Akt
p38 MAPK
|
Cancer
|
|
Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
|
-
- HY-116514
-
|
|
Farnesyl Transferase
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
(S)-(-)-Perillyl alcohol, a monoterpene, is an orally active farnesyl transferase and geranylgeranyl transferase inhibitor. (S)-(-)-Perillyl alcohol up-regulates the mannose-6-phosphate receptor, facilitating TGF-β1 activation and cytostasis,. (S)-(-)-Perillyl alcohol induces apoptosis in cancer cells, modulates cyclin D1 and AP-1 activity. (S)-(-)-Perillyl alcohol exhibits antitumor activity against sarcoma tumors in mice. (S)-(-)-Perillyl alcohol can be used for the research of squamous cell carcinoma of the esophagus and sarcoma 180 .
|
-
- HY-N6954
-
|
|
ATM/ATR
STAT
CDK
Hedgehog
|
Inflammation/Immunology
Cancer
|
|
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active .
|
-
- HY-E70718
-
|
|
FGFR
|
Cancer
|
|
FGFR3 activating mutations are drivers of malignancy in several human tissues, including bladder, lung, cervix, and blood. FGFR3 G697C is a mutant of FGFR3 that may be present in oral squamous cell carcinoma. FGFR3 G697C increases FGFR3 auto-phosphorylation. FGFR3 G697C Recombinant Human Active Protein Kinase is a recombinant FGFR3 G697C protein that can be used to study FGFR3 G697C-related functions .
|
-
- HY-151341
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
HIF-1/2α-IN-1 is an orally active HIF-2α inhibitor. HIF-1/2α-IN-1 inhibits HIF-2α activity with an IC50 value of 0.92 μM. HIF-1/2α-IN-1 also can decrease HIF-1α levels. HIF-1/2α-IN-1 can be used for the research of clear cell renal cell carcinoma (ccRCC) .
|
-
- HY-159803
-
|
6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin
|
Endogenous Metabolite
|
Cancer
|
|
IST-622 (6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin) is an anti-tumor agent with significant growth inhibitory activity. IST-622 exhibits significant anti-tumor effects against a variety of mouse tumors such as P388 and L1210 leukemias, B16 melanoma, Lewis lung carcinoma, Colon 26 and Colon 38 adenocarcinomas, and M5076 reticulum cell sarcoma. IST-622 was orally administered and the results showed efficacy in different tumor types. In addition, IST-622 provided significant inhibitory effects against two human tumor xenograft models: large cell lung carcinoma (Lu-116) and gastric adenocarcinoma (St-4). IST-622 also exhibited significant growth inhibitory activity against P388 leukemia in vitro, with a half inhibitory concentration (IC50) more than 20 times lower than CT .
|
-
- HY-175757
-
|
|
ClpP
Apoptosis
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
Cancer
|
|
HsClpP activator-2 is an orally active HsClpP agonist with a KD of 40 nM. HsClpP activator-2 potently inhibits SCLC cells including H69 (IC50 = 0.17 μM) and H82 (IC50 = 0.19 μM). HsClpP activator-2 disrupts mitochondrial membrane potential (MMP), as well as induces apoptosis and ROS in H82 cells. HsClpP activator-2 significantly inhibits tumor growth in non-SMC xenograft models with a tumor growth inhibition. HsClpP activator-2 can be used for the study of small cell lung carcinoma (SCLC) .
|
-
- HY-120548
-
|
|
TGF-β Receptor
Integrin
Raf
RIP kinase
ERK
|
Cancer
|
|
KBU2046 is an orally active transforming growth factor-β (TGF-β1) inhibitor. KBU2046 reduces integrin family protein expression, decreases Raf, RIPK1 and ERK phosphorylation to deactivate the ERK signaling pathway, and down-regulates genes linked to TGF-β1 maturation. KBU2046 suppresses tumor cell motility, impedes cancer invasion and metastasis, and inhibits human ESCC growth and metastasis in a murine model. KBU2046 can be used for the researches of triple-negative breast cancer and esophageal squamous cell carcinoma .
|
-
- HY-13241A
-
|
LY2228820
|
p38 MAPK
Autophagy
|
Cancer
|
|
Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC50 of 5.3 nmol/L against human p38α and an IC50 of 3.2 nmol/L against human p38β. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma .
|
-
- HY-17509
-
|
SC 046; SC 46; SC 59046
|
COX
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Deracoxib (SC 046; SC 59046), an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas .
|
-
- HY-10261AR
-
|
BIBW 2992MA2 (Standard)
|
Reference Standards
EGFR
Autophagy
Apoptosis
c-Met/HGFR
Akt
p38 MAPK
|
Cancer
|
|
Afatinib (dimaleate) (Standard) is the analytical standard of Afatinib (dimaleate). This product is intended for research and analytical applications. Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .
|
-
- HY-N3651
-
|
|
Bacterial
Reactive Oxygen Species (ROS)
Apoptosis
PI3K
Akt
mTOR
|
Infection
Cancer
|
|
Curzerenone is an orally active sesquiterpene compound and Antibacterial agent. Curzerenone can be isolated from Curcuma zedoaria and Curcuma aeruginosa plants. Curzerenone increases ROS levels, activates Apoptotic signaling pathways, and attenuates the PI3K/AKT/mTOR signaling pathway. Curzerenone exhibits anticancer activity against liver cancer and cervical cancer. Curzerenone has antioxidant effects. Curzerenone shows weak antibacterial activity against Escherichia coli. Curzerenone can be used in research related to hepatocellular carcinoma, cervical cancer, and Escherichia coli infection .
|
-
- HY-N12445
-
|
|
Topoisomerase
Caspase
Apoptosis
SOD
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Quercetin-3'-O-glucoside is an orally active flavonoid glycoside. Quercetin-3'-O-glucoside reduces liver glucose-6-phosphatase activity, alters serum insulin and glucose levels, and regulates the activities of antioxidant enzymes in the liver and kidney. Quercetin-3'-O-glucoside inhibits DNA topoisomerase II, induces S-phase cell cycle arrest and caspase-3-mediated apoptosis in hepatocellular carcinoma cells. Quercetin-3'-O-glucoside selectively inhibits EGFR-mediated signaling pathways targeting AKT, ERK1/2, FAK and MEK1/2. Quercetin-3'-O-glucoside inhibits growth factor-induced migration and invasion in pancreatic cancer cells. Quercetin-3'-O-glucoside exerts free radical scavenging effects. Quercetin-3'-O-glucoside is applicable to research related to pancreatic cancer, diabetes, hepatocellular carcinoma and malignant tumors .
|
-
- HY-N8013
-
|
|
Others
|
Cancer
|
|
5-O,8-Dimethylophiopogonanone B is a homoisoflavanone found in the tuberous roots of Ophiopogon japonicus. 5-O,8-Dimethylophiopogonanone B shows cytotoxicity against cancer cells. 5-O,8-Dimethylophiopogonanone B can be used for the research of cancer, such as breast cancer .
|
-
- HY-151344
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
HIF-1/2α-IN-2 is an inhibitor of HIF-1/2α. HIF-1/2α-IN-2 decrease HIF-1/2α levels and induces iron starvation response by targeting Iron Sulfur Cluster Assembly 2 (ISCA2) .
|
-
- HY-179033
-
|
|
Nuclear Hormone Receptor 4A/NR4A
Apoptosis
ASK1
JNK
p38 MAPK
|
Cancer
|
|
Nur77 antagonist 2 (Compound 12b) is an orally active Nur77 antagonist with a KD value of 0.42 μM. Nur77 antagonist 2 exhibits proliferative activity on liver cancer cells. Nur77 antagonist 2 stabilizes Nur77 by inhibiting its ubiquitin-proteasomal degradation,
leading to Nur77-dependent apoptosis via the ASK1-JNK/p38 pathway. Nur77 antagonist 2 inhibits tumor growth in the HCCLM3 xenograft model. Nur77 antagonist 2 can be used for the study of hepatocellular carcinoma (HCC) .
|
-
- HY-N2217R
-
|
|
Reference Standards
Akt
mTOR
p38 MAPK
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Rotundic acid (Standard) is the analytical standard of Rotundic acid (HY-N2217). This product is intended for research and analytical applications. Rotundic acid is an orally effective triterpenoid with a Kd value of 51.3 µM for PTP1B. Rotundic acid downregulates the AKT/mTOR pro-survival pathway and modulates the MAPK pathway. Rotundic acid induces cell cycle S-phase arrest, DNA damage and apoptosis; it inhibits migration, invasion, angiogenesis and proliferation of cancer cells. Rotundic acid improves leptin sensitivity, regulates gut microbiota and reduces cellular senescence. Rotundic acid can be used in research related to hepatocellular carcinoma, obesity, aging, acute lung injury and type 2 diabetes .
|
-
- HY-177796
-
|
|
Apoptosis
CDK
Caspase
PARP
|
Cancer
|
|
TMLB-C16 is a potent and orally active B3GAT3 inhibitor with a KD of 3.962 μM. TMLB-C16 suppresses proliferation and migration, and induces cell cycle arrest and apoptosis in MHCC-97H (IC50 = 6.53 μM) and HCCLM3 cells (IC50 = 6.22 μM). TMLB-C16 inhibits tumor growth in both MHCC-97H and HCCLM3 xenograft tumor mouse models without causing obvious toxicity. TMLB-C16 can be used for hepatocellular carcinoma research .
|
-
- HY-183058
-
|
|
Histone Methyltransferase
|
Cancer
|
|
EZM8266 is an orally active and selective G9a (EHMT2) histone methyltransferase inhibitor with a human EHMT2 IC50 of 1 pM. EZM8266 reduces repressive H3K9me2 marks at immune-stimulatory gene and endogenous retroviral element promoters. EZM8266 reduces colony formation, migration, and invasion of cancer cells. EZM8266 enhances IFN-γ response, increases MHC class I expression, and enhances CXCL10-mediated T cell recruitment in cancer cells. EZM8266 can be used for the research of hepatocellular carcinoma .
|
-
- HY-148807C
-
|
QC8222 sodium; TACH 101 sodium
|
Apoptosis
Histone Demethylase
|
Cancer
|
|
Zavondemstat (QC8222; TACH 101) sodium is an orally active pan-KDM4 inhibitor, with a IC50 ≤ 0.08 μM against human KDM4A-D and a Kᵢ of 0.52 μM against human KDM4C. Zavondemstat sodium induces cell apoptosis, causes S-phase cell cycle arrest, reduces the population of tumor-initiating cells and inhibits cancer cell proliferation. Zavondemstat sodium suppresses tumor growth and induces tumor regression in mouse xenograft models. Zavondemstat sodium can be used for the research of various cancers including colorectal cancer, esophageal squamous cell carcinoma and triple-negative breast cancer .
|
-
- HY-10261E
-
|
(R)-BIBW 2992
|
EGFR
c-Met/HGFR
p38 MAPK
|
Cancer
|
|
(R)-Afatinib ((R)-BIBW 2992) is the Afatinib isomer. Afatinib (HY-10261) is an orally active, potent and irreversible dual specificity inhibitor of?ErbB?family (EGFR?and?HER2), with?IC50?values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for?EGFR wt, EGFR L858R,?EGFR L858R/T790M?and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung?cancer?(NSCLC) and gastric?cancer .
|
-
- HY-N10009
-
|
|
NF-κB
TNF Receptor
COX
ERK
p38 MAPK
Sirtuin
|
Inflammation/Immunology
|
|
Cudraflavone B is a prenylated flavonoid with anti-inflammatory and anti-tumor properties. Cudraflavone B is also a dual inhibitor of COX-1 and COX-2. Cudraflavone B blocks the translocation of nuclear factor κB (NF-κB) from the cytoplasm to the nucleus in macrophages. Thus, Cudraflavone B inhibits tumor necrosis factor α (TNFα) gene expression and secretion. Cudraflavone B also triggers the mitochondrial apoptotic pathway, activates NF-κB, the MAPK p38, and ERK, and induced the expression of SIRT1. Thus Cudraflavone B inhibits the growth of human oral squamous cell carcinoma cells .
|
-
- HY-N1535
-
|
Rubescensine B
|
RIP kinase
Apoptosis
Reactive Oxygen Species (ROS)
JAK
STAT
PI3K
Akt
Sirtuin
Necroptosis
Amyloid-β
|
Neurological Disease
Cancer
|
|
Ponicidin (Rubescensine B) is an orally active RIPK1 inhibitor with a Kd value of 135 nM. Ponicidin inhibits the JAK2/STAT3 pathway to induce apoptosis, activates the PI3K/Akt pathway, upregulates SIRT1 expression, alleviates oxidative stress, suppresses inflammatory responses and necroptosis, and blocks cell cycle progression. Ponicidin induces ROS production to exert antiproliferative and antiviral effects, while also improving cognitive function and reducing Aβ plaque deposition. Ponicidin can be used in studies related to hepatocellular carcinoma, Alzheimer's disease, and gastric cancer .
|
-
- HY-N6576
-
|
|
p38 MAPK
ERK
JNK
IAP
PARP
Apoptosis
Caspase
|
Cancer
|
|
Hellebrigenin is an inhibitor that selectively targets the MAPK signaling pathway (ERK, p38, JNK) and XIAP, and can inhibit Akt expression and phosphorylation. Hellebrigenin can activate endogenous apoptosis pathways (such as mitochondrial membrane potential disruption, Caspase family activation, PARP cleavage), downregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) and upregulate pro-apoptotic proteins (Bax, Bak). Hellebrigenin can also induce DNA double-strand breaks to activate the ATM pathway. Hellebrigenin can inhibit tumor cell proliferation and clone formation, and is mainly used in the study of oral squamous cell carcinoma, liver cancer and other cancers .
|
-
- HY-N17359
-
|
|
Drug Derivative
|
Cancer
|
|
Mulberrofuran W is a 2-arylbenzofuran with a farnesyl group that exists in the root bark of Morus mongolica. It also acts as a cytotoxic agent with low cytotoxicity and weak tumor specificity .
|
-
- HY-147504
-
|
|
Apoptosis
Caspase
Bcl-2 Family
|
Cancer
|
|
Anticancer agent 63 (compound 3h) shows active in reducing the viability of different cancer cell lines, including SW480, HeLa, A549 and MCF-7, with IC50 values at 24 h of 4.9, 11.5, 9.4, and 3.4 μM, respectively. Anticancer agent 63 induce apoptosis in MCF-7 cells via down-regulating the expression of Bcl-2 and up-regulating the expression of IL-2 and Caspase-3. Anticancer agent 63 also shows antioxidant activity .
|
-
- HY-168428
-
|
|
Histone Acetyltransferase
Apoptosis
|
Cancer
|
|
CHI-KAT8i5 is a selective and orally active KAT8 inhibitor with a KD value of 19.72 μM. CHI-KAT8i5 does not bind to other proteins in HAT family (KAT2A, KAT2B, KAT5, and KAT7). CHI-KAT8i5 induces cancer cell apoptosis. CHI-KAT8i5 suppresses esophageal squamous cell carcinoma (ESCC) growth through targeting KAT8/c-Myc signaling pathway .
|
-
- HY-P990173
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer .
|
-
- HY-10226R
-
|
R306465 (Standard)
|
Reference Standards
Apoptosis
HDAC
|
Cancer
|
|
JNJ-16241199 (Standard) is the analytical standard of JNJ-16241199 (HY-10226). This product is intended for research and analytical applications. JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases
the expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .
|
-
- HY-148807
-
|
QC8222 free base; TACH 101 free base
|
Histone Demethylase
Apoptosis
|
Cancer
|
|
Zavondemstat (QC8222 free base; TACH 101 free base) is an orally active pan-KDM4 inhibitor, with a IC50 ≤ 0.08 μM against human KDM4A-D and a Kᵢ of 0.52 μM against human KDM4C. Zavondemstat induces cell apoptosis, causes S-phase cell cycle arrest, reduces the population of tumor-initiating cells and inhibits cancer cell proliferation. Zavondemstat suppresses tumor growth and induces tumor regression in mouse xenograft models. Zavondemstat can be used for the research of various cancers including colorectal cancer, esophageal squamous cell carcinoma and triple-negative breast cancer .
|
-
- HY-152830
-
|
Q702
|
c-Fms
TAM Receptor
MHC
|
Cancer
|
|
Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .
|
-
- HY-N6954R
-
|
|
Reference Standards
ATM/ATR
STAT
CDK
Hedgehog
|
Inflammation/Immunology
Cancer
|
|
Garcinone C (Standard) is the analytical standard of Garcinone C. This product is intended for research and analytical applications. Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active .
|
-
- HY-17509R
-
|
SC 046 (Standard); SC 46 (Standard); SC 59046 (Standard)
|
Reference Standards
COX
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Deracoxib (SC 046; SC 59046) (Standard) is the analytical standard of Deracoxib (HY-17509). This product is intended for research and analytical applications. Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas
|
-
- HY-116514R
-
|
|
Reference Standards
Farnesyl Transferase
Apoptosis
Endogenous Metabolite
|
Cancer
|
|
(S)-(-)-Perillyl alcohol (Standard) is the analytical standard of (S)-(-)-Perillyl alcohol (HY-116514). This product is intended for research and analytical applications. (S)-(-)-Perillyl alcohol, a monoterpene, is an orally active farnesyl transferase and geranylgeranyl transferase inhibitor. (S)-(-)-Perillyl alcohol up-regulates the mannose-6-phosphate receptor, facilitating TGF-β1 activation and cytostasis,. (S)-(-)-Perillyl alcohol induces apoptosis in cancer cells, modulates cyclin D1 and AP-1 activity. (S)-(-)-Perillyl alcohol exhibits antitumor activity against sarcoma tumors in mice. (S)-(-)-Perillyl alcohol can be used for the research of squamous cell carcinoma of the esophagus and sarcoma 180.
|
-
- HY-155033
-
|
|
Stearoyl-CoA Desaturase (SCD)
DNA/RNA Synthesis
Apoptosis
Autophagy
mTOR
Influenza Virus
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
SSI-4 is an orally active stearoyl-CoA desaturase (SCD1) inhibitor with an EC50 of 1.9 nM against mouse SCD1. SSI-4 blocks the conversion of saturated fatty acids to monounsaturated fatty acids, reducing the production of oleic acid and palmitoleic acid. SSI-4 induces lipid peroxidation, endoplasmic reticulum stress, DNA damage and activates apoptotic mechanisms. SSI-4 inhibits mTORC1 activity, suppresses B cell proliferation and antibody production, and induces autophagy. SSI-4 is applicable to research on cancers such as acute myeloid leukemia and renal cell carcinoma, as well as influenza infections .
|
-
- HY-100008R
-
|
NIK333 (Standard)
|
Reference Standards
RAR/RXR
SphK
Autophagy
HCV
|
Infection
Cancer
|
|
Peretinoin (Standard) is the analytical standard of Peretinoin. This product is intended for research and analytical applications. Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1[1]. Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression[2]. Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC50 of 9 μM[3].
|
-
- HY-W661499
-
|
|
Phosphatase
Apoptosis
Reactive Oxygen Species (ROS)
Caspase
|
Cancer
|
|
Orellanine, a nephrotoxic alkaloid found in Cortinarius orellanus, is an orally active and selective non-competitive inhibitor of alkaline phosphatase. Orellanine chelates iron, generates reactive oxygen species (ROS), induces DNA scission, forms ortho-semiquinone radicals, downregulates antioxidant defenses, and inhibits mitochondrial function. Orellanine induces caspase 8/9-mediated apoptosis. Orellanine inhibits synthesis of proteins, RNA, DNA, and mitochondrial protein synthesis, with metabolic activation required for cell-free protein synthesis inhibition. Orellanine can be used for the research of metastatic clear cell renal cell carcinoma, acute renal failure, chronic renal insufficiency, and kidney damage .
|
-
- HY-183772
-
|
|
Autophagy
Apoptosis
Caspase
Bcl-2 Family
|
Cancer
|
|
TBC1D2-IN-1 is a potent orally active and selective TBC1D2 inhibitor with a Kd of 1.1 μM. TBC1D2-IN-1 selectively inhibits TBC1D2-mediated GTP hydrolysis on RAB7A-GTP, promotes RAB7A accumulation on lysosomal membranes, and induces apoptosis and autophagy. TBC1D2-IN-1 exerts selective antiproliferative activity cancer cells. TBC1D2-IN-1 can be used for the research of cervical carcinoma .
|
-
- HY-N2282
-
|
Zingiberensis newsaponin
|
Aldose Reductase
JAK
STAT
Autophagy
Apoptosis
NF-κB
SOD
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Zingiberen Newsaponin (Zingiberensis newsaponin) is an orally active type of steroid saponin compound. Zingiberen Newsaponin exerts anti-hepatocellular carcinoma (HCC) effects by inhibiting autophagy and the AKR1C1/JAK2/STAT3 pathway. Zingiberen Newsaponin activates oxidative stress (upregulates ROS and MDA) and mitochondrial pathways, promoting cancer cell apoptosis. Zingiberen Newsaponin alleviates cerebral ischemia-reperfusion (I/R) injury by decreasing the concentration of pro-inflammatory cytokines and inhibits NF-κB. Zingiberen Newsaponin can enhance the activity of SOD, eliminate free radicals and protect nerve cells. Zingiberen Newsaponin induces platelet aggregation .
|
-
- HY-172885
-
|
|
DNA/RNA Synthesis
MicroRNA
Apoptosis
Pyroptosis
|
Cancer
|
|
TRBP-IN-1 (Compound 13j) is an orally active TAR RNA binding protein 2 (TRBP) inhibitor (IC50: 12.72 μM). TRBP-IN-1 has significant anti-hepatocellular carcinoma (HCC) activity and can inhibit the proliferation and metastasis of HCC cells (HCCLM3 cells (IC50: 18.96 μM); SK-Hep-1 cells (IC50: 16.45 μM)). TRBP-IN-1 regulates miRNA biogenesis and inhibits oncogenic miRNA expression by targeting TRBP. TRBP-IN-1 induces apoptosis and pyroptosis in HCC cells by inhibiting the level of miRNA. TRBP-IN-1 can be used for targeted therapy research of HCC .
|
-
- HY-17509S
-
|
SC 046-d3; SC 46-d3; SC 59046-d3
|
Isotope-Labeled Compounds
COX
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Deracoxib-d3 (SC 046-d3; SC 59046-d3) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.
|
-
- HY-152830A
-
|
Q702 TFA
|
c-Fms
TAM Receptor
MHC
|
Cancer
|
|
Adrixetinib (Q702) TFA is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib TFA acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib TFA increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib TFA upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib TFA shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib TFA is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .
|
-
- HY-W703540
-
|
SC 046-d4; SC 46-d4; SC 59046-d4
|
Isotope-Labeled Compounds
Apoptosis
COX
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Deracoxib-d4 (SC 046-d4; SC 59046--d4) is deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.
|
-
- HY-148807A
-
|
QC8222; TACH 101
|
Apoptosis
Histone Demethylase
|
Cancer
|
|
Zavondemstat (QC8222; TACH 101) L-lysine is an orally active pan-KDM4 inhibitor, with a IC50 ≤ 0.08 μM against human KDM4A-D and a Kᵢ of 0.52 μM against human KDM4C. Zavondemstat L-lysine induces cell apoptosis, causes S-phase cell cycle arrest, reduces the population of tumor-initiating cells and inhibits cancer cell proliferation. Zavondemstat L-lysine suppresses tumor growth and induces tumor regression in mouse xenograft models. Zavondemstat L-lysine can be used for the research of various cancers including colorectal cancer, esophageal squamous cell carcinoma and triple-negative breast cancer .
|
-
- HY-16475
-
|
|
Hedgehog
|
Cancer
|
|
TAK-441 is a highly potent and orally active hedgehog (Hh) signaling inhibitor with an IC50value of 4.4 nM. TAK-441 has strong antitumor activity in solid tumors .
|
-
- HY-N17633
-
|
|
Others
|
Cancer
|
|
Mulberrofuran L is a 2-arylbenzofuran compound. Mulberrofuran L exhibits certain cytotoxicity against tumor cells. Mulberrofuran L can be used in tumor research .
|
-
- HY-10626
-
|
|
LXR
FXR
ROR
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα . T0901317 activates FXR with an EC50 of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .
|
-
- HY-10626R
-
|
|
Reference Standards
LXR
FXR
ROR
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
T0901317 (Standard) is the analytical standard of T0901317. This product is intended for research and analytical applications. T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα . T0901317 activates FXR with an EC50 of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .
|
-
- HY-149136
-
|
|
Integrin
TGF-beta/Smad
|
Inflammation/Immunology
|
|
MORF-627 is a highly selective, orally active integrin αvβ6 inhibitor. By blocking TGF-β1 activation and pSMAD2 signaling, MORF-627 significantly reduces collagen deposition, epithelial-mesenchymal transition markers, and structural changes in fibrotic cells. MORF-627 exhibits significant antifibrotic efficacy without genotoxicity in idiopathic pulmonary fibrosis models. However, MORF-627 induces bladder epithelial proliferation and early invasive urothelial carcinoma in cynomolgus monkeys and human cells, and this toxic effect can be reversed by exogenous TGF-β. MORF-627 can be used for studying the pathological mechanisms of pulmonary fibrosis and evaluating drug safety .
|
-
- HY-10071
-
Y-27632
Maximum Cited Publications
533 Publications Verification
|
ROCK
NADPH Oxidase
mTOR
Reactive Oxygen Species (ROS)
NF-κB
Apoptosis
Akt
Autophagy
PAK
Ras
|
Cancer
|
|
Y-27632 is a ROCK inhibitor with Ki values of 220 nM and 300 nM for ROCK1 and ROCK2, respectively. Y-27632 exerts anti-inflammatory and immunomodulatory effects in systemic lupus erythematosus models by inhibiting the ROCK/NF-κB pathway. Y-27632 enhances autophagy by inhibiting the AKT/mTOR pathway, thereby inducing apoptosis apoptosis in oral squamous cell carcinoma. Y-27632 induces the formation of tunneling nanotubes in ARPE-19 cells and significantly enhances mitochondrial transfer through these channels. Y-27632 promotes neurite outgrowth in PC12 cells by activating the Rac1/NOX1/ROS/AKT/PAK1 signaling cascade .
|
-
- HY-10071A
-
|
|
ROCK
NF-κB
Apoptosis
Autophagy
Akt
mTOR
NADPH Oxidase
Reactive Oxygen Species (ROS)
PAK
Ras
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Y-27632 hydrochloride hydrate is a ROCK inhibitor with Ki values of 220 nM and 300 nM for ROCK1 and ROCK2, respectively. Y-27632 hydrochloride hydrate exerts anti-inflammatory and immunomodulatory effects in systemic lupus erythematosus models by inhibiting the ROCK/NF-κB pathway. Y-27632 hydrochloride hydrate enhances autophagy by inhibiting the AKT/mTOR pathway, thereby inducing apoptosis apoptosis in oral squamous cell carcinoma. Y-27632 hydrochloride hydrate induces the formation of tunneling nanotubes in ARPE-19 cells and significantly enhances mitochondrial transfer through these channels. Y-27632 hydrochloride hydrate promotes neurite outgrowth in PC12 cells by activating the Rac1/NOX1/ROS/AKT/PAK1 signaling cascade .
|
-
- HY-107272
-
|
22-Epidelavinone
|
Cholinesterase (ChE)
Apoptosis
Bcl-2 Family
Caspase
Interleukin Related
TNF Receptor
Toll-like Receptor (TLR)
MyD88
NF-κB
p38 MAPK
|
Inflammation/Immunology
Cancer
|
|
Chuanbeinone (22-Epidelavinone) is an orally active alkaloid found in Fritillaria pallidiflora. Chuanbeinone shows cytotoxicity against mutiple cancer cells and can induces apoptosis and S phase arrest. Chuanbeinone downregulates Bcl-2, upregulates Bax, and activates caspase-3. Chuanbeinone exerts anti-inflammatory and antitussive effects by reducing pro-inflammatory cytokine (IL-1β, IL-6 and TNF-α) production and mRNA expression, and inhibiting TRIF-, MyD88-, NF-κB-, and MAPK-dependent signaling pathways. Chuanbeinone inhibits AChE and BChE with IC50 values of 7.7 and 0.7 μM. Chuanbeinone can be used for the researches of lung carcinoma, cough, inflammatory diseases .
|
-
- HY-W725179
-
|
|
EBV
|
Cancer
|
|
VK-2019 is an orally bioavailable selective inhibitor of EBNA1. By binding to the protein-DNA interface to interfere with the recruitment and anchoring of the viral DNA replication machinery, VK-2019 effectively blocks the replication and proliferation of EBV in latently infected cells. VK-2019 reduces the copy number and gene expression level of Epstein-Barr virus in tumor cells, decreases the number of EBER-positive cells, and exhibits significant antiviral, immunomodulatory and antiproliferative activities. VK-2019 successfully inhibits tumor growth in EBV-dependent xenograft models. VK-2019 has favorable systemic exposure and acceptable safety profiles, and is widely used in research on advanced nasopharyngeal carcinoma and various EBV-associated cancers .
|
-
- HY-176847
-
|
|
Orphan Nuclear Receptor
Apoptosis
|
Cancer
|
|
DHQZ-17 is a HNF4A inhibitor. DHQZ-17 triggers apoptosis in head and neck squamous cell carcinoma cells. DHQZ-17 can be used for the research of head & neck squamous cell carcinoma .
|
-
- HY-15947G
-
|
GDC-0994
|
ERK
c-Myc
Hexokinase
Lactate Dehydrogenase
|
Cancer
|
|
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
|
-
- HY-W800535
-
|
|
NF-κB
p38 MAPK
mTOR
Topoisomerase
AMPK
Apoptosis
Cholinesterase (ChE)
HIF/HIF Prolyl-Hydroxylase
β-catenin
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Cryptolepine is an orally active multi-potent alkaloid with anti-cancer, anti-bacterial, anti-viral, anti-malarial, anti-inflammatory, anti-hyperglycemic, relieve pain and other properties. Cryptolepine acts as an inhibitor of c-Myc, mTOR, NF-κB, HIF-1, MAPK and an activator of AMPKα1/2. It intercalates into DNA, inhibits topoisomerase II (Top II), disrupts mitochondrial dynamics and induces apoptosis. Cryptolepine also exhibits anti-plasmodial and cholinesterase inhibitory activities. Cryptolepine can be used in research related to tumors (melanoma, hepatocellular carcinoma, mammary adenocarcinoma, etc.), malaria, inflammatory diseases and diabetes, particularly in studies focused on inhibiting tumor growth and anti-plasmodial infection .
|
-
- HY-P99139
-
|
|
Interleukin Related
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .
|
-
- HY-P1130
-
|
Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
M871 (Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide) is an orally active and selective galanin receptor type 2 (GalR2) antagonist. M871 exhibits Ki values of 13.1 nM, 420 nM and >10 μM for GalR2, GalR1 and GalR3 respectively. M871 relieves the mice allergic rhinitis by reducing IgE production, as well as the number of B cells in tissues. M871 can inhibit the nerve invasion of salivary adenoid cystic carcinoma (SACC) and alleviate myocardial ischemia-reperfusion injury. M871 can be used for research on GalR2-related diseases (such as epilepsy, pain) .
|
-
- HY-N19853
-
|
|
Drug Derivative
|
Cancer
|
|
Mangiferonic acid is a triterpenoid found in the stems of Vatica diospyroides. Mangiferonic acid can be used for cancer research .
|
-
- HY-W278867
-
|
trans-Pinosylvin dimethyl ether
|
Cholinesterase (ChE)
|
Neurological Disease
Inflammation/Immunology
|
|
trans-3,5-Dimethoxystilbene (trans-Pinosylvin dimethyl ether) is a natural stilbenoid metabolite. trans-3,5-Dimethoxystilbene acts as an acetylcholinesterase inhibitor with a IC50 of 9 μM against Electrophorus electricus acetylcholinesterase. trans-3,5-Dimethoxystilbene binds to acetylcholinesterase and blocks acetylcholine hydrolysis, thereby increasing acetylcholine levels in the cholinergic synaptic cleft. trans-3,5-Dimethoxystilbene can be used in the research of neurodegenerative diseases such as Alzheimer's disease .
|
-
- HY-124295
-
|
ABT-301; MPT0E028; TMU-C-0012
|
HDAC
Akt
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Imofinostat (ABT-301; MPT0E028) is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. Imofinostat has a weak inhibitory effect on HDAC8 (IC50 of 2.5 μM), but no inhibitory effect on HDAC4 (IC50>10 μM). Imofinostat reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. Imofinostat has a broad-spectrum antitumor activity, including colorectal cancer, B-cell lymphoma, non-small cell lung carcinoma (NSCLC), and pancreatic cancer, while also showing therapeutic potential in non-tumor diseases like emphysema and pulmonary fibrosis .
|
-
- HY-N17816
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
α-synuclein
Succinate Dehydrogenase
Bcl-2 Family
Caspase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Tambulin is an orally active flavonol compound found in Zanthoxylum armatum. Tambulin can inhibit cell proliferation, induce apoptosis and inhibit ROS production. Tambulin upregulates cleaved caspase-3, cleaved caspase-9, and Bax, downregulates Bcl-2 levels. Tambulin can stimulate glucose-dependent insulin secretion and induce endothelium-independent vasorelaxation. Tambulin binds to succinate dehydrogenase (SDH) (Ki = 11.02 μM) and shows significant ferric reducing power. Tambulin can enhances oxidative stress resistance, reduces, lipofuscin deposits, lipid levels, α-synuclein levels, improves locomotary behavior, and dopamine levels in in age-synchronized L1 hermaphrodite Caenorhabditis elegans models of ageing and Parkinson's disease. Tambulin can be used for the researches of Parkinson's disease, lung squamous cell carcinoma, and diabetes .
|
-
- HY-10201
-
|
Bay 43-9006
|
Raf
VEGFR
FLT3
Autophagy
Apoptosis
STAT
Akt
MMP
Cadherin
p38 MAPK
ERK
MEK
PI3K
PARP
Bcl-2 Family
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
|
-
- HY-10201A
-
|
Bay 43-9006 tosylate
|
Raf
VEGFR
FLT3
Autophagy
Apoptosis
STAT
Akt
MMP
Cadherin
p38 MAPK
ERK
MEK
PI3K
PARP
Bcl-2 Family
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .
|
-
- HY-N2445
-
|
|
Apoptosis
Akt
JNK
PERK
Caspase
PARP
MDM-2/p53
IAP
Reactive Oxygen Species (ROS)
SOD
FABP
Autophagy
AMPK
mTOR
GLUT
EGFR
PI3K
HSP
VEGFR
FAK
|
Cancer
|
|
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .
|
-
- HY-N12378A
-
|
|
AMPK
FASTK
Sirtuin
ROCK
Keap1-Nrf2
Toll-like Receptor (TLR)
Apoptosis
PKA
ERK
NF-κB
Epigenetic Reader Domain
Caspase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
α-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptotic agent. α-Patchoulene inhibits the NF-κB, TLR4, and cAMP/PKA/CREB signaling pathways; activates the Sirt1/Nrf2 and AMPK signaling pathways; and targets Fas/FasL, Caspase-3, ERK1/2, ROCK1/MLC2 for inhibition. α-Patchoulene regulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae. α-Patchoulene can be used in research related to various inflammatory, ischemic, fibrosis-associated diseases, as well as hepatocellular carcinoma .
|
-
- HY-183335
-
|
|
Smo
Hedgehog
Gli
Apoptosis
Caspase
|
Cancer
|
|
Anticancer agent 321 is a Smoothened (SMO) inhibitor with a human IC50 of 0.12 μM, enhanced aqueous solubility, good plasma and metabolic stability, moderate therapeutic index, preliminary safety profile, and moderate oral bioavailability in rats.Anticancer agent 321 binds to SMO’s 7-transmembrane helical channel, forming hydrogen bonds with Asp384 and hydrophobic/π-π interactions with His470, Phe391, Tyr394, stabilizing SMO’s inactive conformation to inhibit Hedgehog/GLI signaling.Anticancer agent 321 inhibits proliferation, suppresses colony formation, induces apoptosis, and downregulates Hedgehog/GLI pathway target genes GLI1, GLI2, Ptch1, HHip in cancer cells.Anticancer agent 321 inhibits tumor growth, downregulates Ki67 and SOX2, and upregulates cleaved-caspase 3 in tumor tissues.Anticancer agent 321 can be used for the research of cutaneous squamous cell carcinoma .
|
-
- HY-P4087B
-
|
|
HIV
|
Others
|
|
Cys(Npys)-(Arg)9 acetate is a synthetic cationic cell-penetrating peptide with a reversible thiol-reactive nitropyridyl (Npys) group. Cys(Npys)-(Arg)9 acetate efficiently mediates the internalization and delivery of various "cargo" such as proteins and antibodies by forming reversible disulfide bonds with surface-exposed cysteine residues. Cys(Npys)-(Arg)9 acetate endows TALEN proteins with cell-penetrating activity, enabling gene knockout in mammalian cells and protein transduction in wheat microspores. Cys(Npys)-(Arg)9 acetate can be conjugated with antibodies to form cationized IgG for enhancing endosomal escape of oligonucleotides, or form siRNA delivery complexes. When the molar ratio of Cys(Npys)-(Arg)9 acetate to loaded molecules is higher than 1:1, it exerts certain cytotoxic effects on cells. Cys(Npys)-(Arg)9 acetate can be used in studies related to oral squamous cell carcinoma and HIV infection .
|
-
- HY-10071R
-
|
|
Reference Standards
mTOR
Ras
ROCK
NADPH Oxidase
NF-κB
Reactive Oxygen Species (ROS)
Akt
Apoptosis
Autophagy
PAK
|
Cancer
|
|
Y-27632 (Standard) is the analytical standard of Y-27632 (HY-10071). This product is intended for research and analytical applications. Y-27632 is a ROCK inhibitor with Ki values of 220 nM and 300 nM for ROCK1 and ROCK2, respectively. Y-27632 exerts anti-inflammatory and immunomodulatory effects in systemic lupus erythematosus models by inhibiting the ROCK/NF-κB pathway. Y-27632 enhances autophagy by inhibiting the AKT/mTOR pathway, thereby inducing apoptosis apoptosis in oral squamous cell carcinoma. Y-27632 induces the formation of tunneling nanotubes in ARPE-19 cells and significantly enhances mitochondrial transfer through these channels. Y-27632 promotes neurite outgrowth in PC12 cells by activating the Rac1/NOX1/ROS/AKT/PAK1 signaling cascade .
|
-
- HY-N12378
-
|
|
NF-κB
Toll-like Receptor (TLR)
PKA
Epigenetic Reader Domain
Keap1-Nrf2
Sirtuin
AMPK
Caspase
FASTK
ERK
ROCK
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
β-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptotic agent. β-Patchoulene inhibits the NF-κB, TLR4, and cAMP/PKA/CREB signaling pathways; activates the Sirt1/Nrf2 and AMPK signaling pathways; and targets Fas/FasL, Caspase-3, ERK1/2, ROCK1/MLC2 for inhibition. β-Patchoulene regulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae. β-Patchoulene can be used in research related to various inflammatory, ischemic, fibrosis-associated diseases, as well as hepatocellular carcinoma .
|
-
- HY-N4087
-
|
|
Mitophagy
Autophagy
Ferroptosis
Interleukin Related
IFNAR
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
Cancer
|
|
Platycodin D2 is an orally active triterpenoid saponin found in Platycodon grandiflorum. Platycodin D2 induces mitophagy in cancer cells through NIX, thereby activating the P21/CyclinA2 pathway and promoting cell senescence. Platycodin D2 induces mitochondrial dysfunction, enhances autophagy, inhibits hepatocellular carcinoma cell proliferation, and exhibits anti-tumor activity against multiple cancer cell types. Platycodin D2 promotes mRNA expression of T-bet, GATA-3, Th1 cytokines IL-2 and IFN-γ, and Th2 cytokines IL-4 and IL-10, enhances splenocyte proliferation, and acts as a vaccine adjuvant with low rabbit red blood cell hemolytic activity. Platycodin D2 induces mitochondrial ROS production, incomplete autophagy, and ferroptosis to inhibit breast cancer cell proliferation. Platycodin D2 can be used for the research of cancer, inflammation and immunology .
|
-
- HY-N13250
-
|
|
Apoptosis
AMPK
Elastase
Bcl-2 Family
Interleukin Related
Caspase
PI3K
Akt
SOD
|
Cardiovascular Disease
|
|
Hawthorn Extract is an orally active hawthorn extract. Hawthorn Extract decreases Bax expression and increases Bcl-2 expression in the aorta. Hawthorn Extract regulates the AMPK signaling pathway, induces apoptosis, enhances the hepatic antioxidant system, and ameliorates symptoms of liver injury, inflammation and cancer. Hawthorn Extract reduces plasma levels of pro-inflammatory factors, increases plasma levels of anti-inflammatory adiponectin, and alleviates atherosclerotic plaque lesions in the aorta. Hawthorn Extract improves symptoms associated with chronic heart failure . Hawthorn Extract inhibits FMLP-induced superoxide anion production, Elastase release, ILB4 generation and calcium signaling in neutrophils, and also reduces LPS-induced cytokine production in neutrophils. Hawthorn Extract induces autophagy and inhibits the proliferation of intestinal stem cells. Hawthorn Extract can be used in research related to atherosclerosis, hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma, chronic heart failure and hypotension .
|
-
- HY-N5112A
-
|
Arnebin 1
|
FGFR
Necroptosis
Apoptosis
CDK
JNK
|
Inflammation/Immunology
|
|
β,β-Dimethylacrylalkannin (Arnebin 1) is an orally active FGFR1 inhibitor (IC50=2.5 μM) and the main active component of Lithospermum erythrorhizon. β,β-Dimethylacrylalkannin blocks downstream signaling by binding to the ATP pocket of FGFR1, and regulates the CDK1/Cdc25C pathway and ROS-JNK axis, thereby inducing G2/M phase arrest, necrosis and apoptosis in cancer cells, and inhibiting tumor proliferation. β,β-Dimethylacrylalkannin also acts as a colistin adjuvant to disrupt the cell membrane of Gram-negative bacteria. β,β-Dimethylacrylalkannin exhibits significant tumor-inhibitory effects with no obvious toxicity in PDX models, but chronic exposure to high doses may alter the relative lung/liver weights of rats, while acute exposure to high doses causes responses such as reduced motor activity. β,β-Dimethylacrylalkannin finds wide application in studies related to hepatocellular carcinoma, colorectal cancer, colistin-resistant bacterial infections, hepatitis and psoriasis .
|
-
- HY-B0766
-
|
SY801
|
Autophagy
Apoptosis
HBV
HCV
HSP
Reactive Oxygen Species (ROS)
Bcl-2 Family
Glutathione S-transferase
p38 MAPK
NF-κB
Microtubule/Tubulin
ERK
JNK
TNF Receptor
Interleukin Related
CDK
Cyclin G-associated Kinase (GAK)
mTOR
P-glycoprotein
Ferroptosis
|
Infection
Inflammation/Immunology
Cancer
|
|
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .
|
-
- HY-162275
-
|
|
Histone Demethylase
Histone Methyltransferase
STAT
|
Cancer
|
|
JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50 = 0.59 μM, Kd = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC50 = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .
|
-
- HY-N0566
-
|
Anemosapogenin
|
Apoptosis
Autophagy
Bcl-2 Family
Caspase
Survivin
p38 MAPK
MMP
|
Cancer
|
|
23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer .
|
-
- HY-N0566R
-
|
Anemosapogenin (Standard)
|
Reference Standards
Apoptosis
Autophagy
Bcl-2 Family
Caspase
Survivin
p38 MAPK
MMP
|
Cancer
|
|
23-Hydroxybetulinic acid (Standard) is the analytical standard of 23-Hydroxybetulinic acid (HY-N0566). This product is intended for research and analytical applications. 23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer.
|
-
- HY-W1130459
-
|
|
Liposome
|
Cancer
|
|
(R)-C12-200 is the (R)-isomer of C12-200 (HY-145405), an ionizable cationic lipid and helper lipid. (R)-C12-200 enables functional mRNA delivery to head and neck squamous cell carcinoma xenograft tumor cells in NU/J immunocompromised mice, with minimal off-target delivery to liver or spleen. (R)-C12-200 can be utilized in the formation of lipid nanoparticles and mRNA delivery .
|
-
- HY-179427
-
|
|
Histone Methyltransferase
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
NSD2/H3K36me2 modulator-1 is an orally active NSD2/H3K36me2 modulator. NSD2/H3K36me2 modulator-1 competitively binds to the SAM pocket of NSD2, potently inhibits NSD2 expression and suppresses H3K36me2 methylation. NSD2/H3K36me2 modulator-1 reverses epithelial-mesenchymal transition (EMT), inhibits cell migration, and induces G0/G1 phase arrest and apoptosis. NSD2/H3K36me2 modulator-1 induces decreased Mitochondrial membrane potential (MMP) and subsequent Reactive oxygen species (ROS) generation. NSD2/H3K36me2 modulator-1 can be used to research the NSD2-targeting epigenetic anticancer strategies for hepatocellular carcinoma (HCC) .
|
-
| Cat. No. |
Nombre del producto |
Type |
-
- HY-159642G
-
|
TYRA-300
|
Fluorescent Dyes
|
|
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
|
-
- HY-135146G
-
|
|
Fluorescent Dyes
|
|
GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma .
|
-
- HY-15947G
-
|
GDC-0994
|
Fluorescent Dyes
|
|
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
|
| Cat. No. |
Nombre del producto |
Type |
-
- HY-W286743
-
|
CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine
|
Biochemical Assay Reagents
|
|
Nε-(Carboxymethyl)-L-lysine (CML) is an orally active advanced glycation end product. Nε-(Carboxymethyl)-L-lysine upregulates the expression of PLK1 and CEP20, and induces the activation of RAGE and ERK/NFκB. Nε-(Carboxymethyl)-L-lysine drives centrosome amplification. Nε-(Carboxymethyl)-L-lysine induces malignant transformation of hepatocytes and promotes the development of hepatocellular carcinoma. Nε-(Carboxymethyl)-L-lysine induces epithelial-mesenchymal transition in osteosarcoma cells and enhances their migration and invasion properties .
|
-
- HY-Y1155
-
|
HMPA
|
Biochemical Assay Reagents
|
|
Hexamethylphosphoramide is an orally active polar aprotic solvent, flame retardant additive, and carcinogen. Hexamethylphosphoramide undergoes cytochrome P-450-mediated N-demethylation to Formaldehyde. Hexamethylphosphoramide induces DNA-protein crosslinks. Hexamethylphosphoramide has been linked to nasal tumors (squamous cell carcinoma, adenoid squamous cell carcinoma), squamous metaplasia, rhinitis, tracheitis, and reversible and irreversible infertility .
|
-
- HY-159642G
-
|
TYRA-300
|
Biochemical Assay Reagents
|
|
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
|
-
- HY-135146G
-
|
|
Biochemical Assay Reagents
|
|
GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma .
|
-
- HY-15947G
-
|
GDC-0994
|
Biochemical Assay Reagents
|
|
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
|
| Cat. No. |
Nombre del producto |
Target |
Research Area |
-
- HY-P1654
-
|
|
Integrin
|
Cancer
|
|
A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .
|
-
- HY-P1130
-
|
Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
M871 (Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide) is an orally active and selective galanin receptor type 2 (GalR2) antagonist. M871 exhibits Ki values of 13.1 nM, 420 nM and >10 μM for GalR2, GalR1 and GalR3 respectively. M871 relieves the mice allergic rhinitis by reducing IgE production, as well as the number of B cells in tissues. M871 can inhibit the nerve invasion of salivary adenoid cystic carcinoma (SACC) and alleviate myocardial ischemia-reperfusion injury. M871 can be used for research on GalR2-related diseases (such as epilepsy, pain) .
|
-
- HY-P2302
-
|
|
Antibiotic
Bacterial
Fungal
|
Infection
Inflammation/Immunology
Cancer
|
|
Defensin HNP-3 human is an α-defensin stored in the azurophilic granules of human neutrophils. Defensin HNP-3 human exerts broad-spectrum bactericidal, antifungal and antiviral activities mainly by forming bacterial membrane pores, and acts as a chemoattractant for monocytes and T cells. Defensin HNP-3 human maintains epithelial integrity to support periodontal tissue homeostasis, and exerts concentration-dependent effects on epithelial cell proliferation, adhesion and bacterial adhesion. Defensin HNP-3 human targets solid tumors and leukemia by inducing single-strand DNA breaks and membrane permeabilization in tumor cells via electrostatic binding and pore formation. Defensin HNP-3 human is abundant in human tongue squamous cell carcinoma and neutrophils infiltrating oral squamous cell carcinoma. Defensin HNP-3 human can be applied to research related to periodontitis and human tongue squamous cell carcinoma .
|
-
- HY-P4087
-
|
|
HIV
|
Infection
Cancer
|
|
Cys(Npys)-(Arg)9 is a synthetic cationic cell-penetrating peptide with a reversible thiol-reactive nitropyridyl (Npys) group. Cys(Npys)-(Arg)9 efficiently mediates the internalization and delivery of various "cargo" such as proteins and antibodies by forming reversible disulfide bonds with surface-exposed cysteine residues. Cys(Npys)-(Arg)9 endows TALEN proteins with cell-penetrating activity, enabling gene knockout in mammalian cells and protein transduction in wheat microspores. Cys(Npys)-(Arg)9 can be conjugated with antibodies to form cationized IgG for enhancing endosomal escape of oligonucleotides, or form siRNA delivery complexes. When the molar ratio of Cys(Npys)-(Arg)9 to loaded molecules is higher than 1:1, it exerts certain cytotoxic effects on cells. Cys(Npys)-(Arg)9 can be used in studies related to oral squamous cell carcinoma and HIV infection .
|
-
- HY-P4087B
-
|
|
HIV
|
Others
|
|
Cys(Npys)-(Arg)9 acetate is a synthetic cationic cell-penetrating peptide with a reversible thiol-reactive nitropyridyl (Npys) group. Cys(Npys)-(Arg)9 acetate efficiently mediates the internalization and delivery of various "cargo" such as proteins and antibodies by forming reversible disulfide bonds with surface-exposed cysteine residues. Cys(Npys)-(Arg)9 acetate endows TALEN proteins with cell-penetrating activity, enabling gene knockout in mammalian cells and protein transduction in wheat microspores. Cys(Npys)-(Arg)9 acetate can be conjugated with antibodies to form cationized IgG for enhancing endosomal escape of oligonucleotides, or form siRNA delivery complexes. When the molar ratio of Cys(Npys)-(Arg)9 acetate to loaded molecules is higher than 1:1, it exerts certain cytotoxic effects on cells. Cys(Npys)-(Arg)9 acetate can be used in studies related to oral squamous cell carcinoma and HIV infection .
|
| Cat. No. |
Nombre del producto |
-
- HY-K6133
-
|
|
|
MCE Human Oral Squamous Carcinoma Organoid Kit includes a basic culture medium for Oral Squamous Carcinoma organoids, as well as culture supplements, and is designed for the effective construction of human Oral Squamous Carcinoma organoids.
|
| Cat. No. |
Nombre del producto |
Target |
Research Area |
Image |
-
- HY-P990173
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer .
|
-
(5)
-
- HY-P99139
-
|
|
Interleukin Related
Reactive Oxygen Species (ROS)
Ferroptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .
|
-
(5)
| Cat. No. |
Nombre del producto |
Category |
Target |
Chemical Structure |
-
- HY-17473
-
-
-
- HY-N2414
-
-
-
- HY-N0864
-
-
-
- HY-N1535
-
-
-
- HY-N2123
-
-
-
- HY-N2115
-
-
-
- HY-N2217
-
-
-
- HY-116514
-
-
-
- HY-N3651
-
-
-
- HY-N2445
-
|
|
Structural Classification
Classification of Application Fields
Piperaceae
Plants
Chalcones
Flavonoids
other families
Phenols
Polyphenols
Piper methysticum G.Forst.
Disease Research Fields
Source Classification
Cancer
|
Apoptosis
Akt
JNK
PERK
Caspase
PARP
MDM-2/p53
IAP
Reactive Oxygen Species (ROS)
SOD
FABP
Autophagy
AMPK
mTOR
GLUT
EGFR
PI3K
HSP
VEGFR
FAK
|
|
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .
|
-
-
- HY-N4087
-
|
|
Triterpenes
Structural Classification
Classification of Application Fields
Terpenoids
Platycodon grandiflorus (Jacq.) A. DC.
Campanulaceae
Plants
Disease Research Fields
Source Classification
Cancer
|
Mitophagy
Autophagy
Ferroptosis
Interleukin Related
IFNAR
Reactive Oxygen Species (ROS)
|
|
Platycodin D2 is an orally active triterpenoid saponin found in Platycodon grandiflorum. Platycodin D2 induces mitophagy in cancer cells through NIX, thereby activating the P21/CyclinA2 pathway and promoting cell senescence. Platycodin D2 induces mitochondrial dysfunction, enhances autophagy, inhibits hepatocellular carcinoma cell proliferation, and exhibits anti-tumor activity against multiple cancer cell types. Platycodin D2 promotes mRNA expression of T-bet, GATA-3, Th1 cytokines IL-2 and IFN-γ, and Th2 cytokines IL-4 and IL-10, enhances splenocyte proliferation, and acts as a vaccine adjuvant with low rabbit red blood cell hemolytic activity. Platycodin D2 induces mitochondrial ROS production, incomplete autophagy, and ferroptosis to inhibit breast cancer cell proliferation. Platycodin D2 can be used for the research of cancer, inflammation and immunology .
|
-
-
- HY-N5112A
-
|
Arnebin 1
|
Quinones
Structural Classification
other families
Classification of Application Fields
Other Diseases
Plants
Naphthalene Quinones
Pteris livida Mett.
Disease Research Fields
|
FGFR
Necroptosis
Apoptosis
CDK
JNK
|
|
β,β-Dimethylacrylalkannin (Arnebin 1) is an orally active FGFR1 inhibitor (IC50=2.5 μM) and the main active component of Lithospermum erythrorhizon. β,β-Dimethylacrylalkannin blocks downstream signaling by binding to the ATP pocket of FGFR1, and regulates the CDK1/Cdc25C pathway and ROS-JNK axis, thereby inducing G2/M phase arrest, necrosis and apoptosis in cancer cells, and inhibiting tumor proliferation. β,β-Dimethylacrylalkannin also acts as a colistin adjuvant to disrupt the cell membrane of Gram-negative bacteria. β,β-Dimethylacrylalkannin exhibits significant tumor-inhibitory effects with no obvious toxicity in PDX models, but chronic exposure to high doses may alter the relative lung/liver weights of rats, while acute exposure to high doses causes responses such as reduced motor activity. β,β-Dimethylacrylalkannin finds wide application in studies related to hepatocellular carcinoma, colorectal cancer, colistin-resistant bacterial infections, hepatitis and psoriasis .
|
-
-
- HY-N6726
-
-
-
- HY-N6954
-
-
-
- HY-N12445
-
|
|
Malvaceae
Structural Classification
Flavonols
Flavonoids
Abelmoschus manihot (Linn.) Medicus
Plants
Source Classification
|
Topoisomerase
Caspase
Apoptosis
SOD
|
|
Quercetin-3'-O-glucoside is an orally active flavonoid glycoside. Quercetin-3'-O-glucoside reduces liver glucose-6-phosphatase activity, alters serum insulin and glucose levels, and regulates the activities of antioxidant enzymes in the liver and kidney. Quercetin-3'-O-glucoside inhibits DNA topoisomerase II, induces S-phase cell cycle arrest and caspase-3-mediated apoptosis in hepatocellular carcinoma cells. Quercetin-3'-O-glucoside selectively inhibits EGFR-mediated signaling pathways targeting AKT, ERK1/2, FAK and MEK1/2. Quercetin-3'-O-glucoside inhibits growth factor-induced migration and invasion in pancreatic cancer cells. Quercetin-3'-O-glucoside exerts free radical scavenging effects. Quercetin-3'-O-glucoside is applicable to research related to pancreatic cancer, diabetes, hepatocellular carcinoma and malignant tumors .
|
-
-
- HY-N2282
-
-
-
- HY-N13250
-
|
|
Cardiovascular Disease
Classification of Application Fields
Rosaceae
Plants
Disease Research Fields
Source Classification
|
Apoptosis
AMPK
Elastase
Bcl-2 Family
Interleukin Related
Caspase
PI3K
Akt
SOD
|
|
Hawthorn Extract is an orally active hawthorn extract. Hawthorn Extract decreases Bax expression and increases Bcl-2 expression in the aorta. Hawthorn Extract regulates the AMPK signaling pathway, induces apoptosis, enhances the hepatic antioxidant system, and ameliorates symptoms of liver injury, inflammation and cancer. Hawthorn Extract reduces plasma levels of pro-inflammatory factors, increases plasma levels of anti-inflammatory adiponectin, and alleviates atherosclerotic plaque lesions in the aorta. Hawthorn Extract improves symptoms associated with chronic heart failure . Hawthorn Extract inhibits FMLP-induced superoxide anion production, Elastase release, ILB4 generation and calcium signaling in neutrophils, and also reduces LPS-induced cytokine production in neutrophils. Hawthorn Extract induces autophagy and inhibits the proliferation of intestinal stem cells. Hawthorn Extract can be used in research related to atherosclerosis, hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma, chronic heart failure and hypotension .
|
-
-
- HY-N0566
-
|
Anemosapogenin
|
Triterpenes
Structural Classification
other families
Classification of Application Fields
Terpenoids
Plants
Disease Research Fields
Source Classification
Cancer
|
Apoptosis
Autophagy
Bcl-2 Family
Caspase
Survivin
p38 MAPK
MMP
|
|
23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer .
|
-
-
- HY-N0746
-
-
-
- HY-119906
-
-
-
- HY-N0885
-
-
-
- HY-109569
-
-
-
- HY-N8420
-
-
-
- HY-W278867
-
-
-
- HY-N12378
-
|
|
Other Terpenoids
Structural Classification
Entada phaseoloides (L.) Merr.
Terpenoids
Labiatae
Plants
Source Classification
|
NF-κB
Toll-like Receptor (TLR)
PKA
Epigenetic Reader Domain
Keap1-Nrf2
Sirtuin
AMPK
Caspase
FASTK
ERK
ROCK
Apoptosis
|
|
β-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptotic agent. β-Patchoulene inhibits the NF-κB, TLR4, and cAMP/PKA/CREB signaling pathways; activates the Sirt1/Nrf2 and AMPK signaling pathways; and targets Fas/FasL, Caspase-3, ERK1/2, ROCK1/MLC2 for inhibition. β-Patchoulene regulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae. β-Patchoulene can be used in research related to various inflammatory, ischemic, fibrosis-associated diseases, as well as hepatocellular carcinoma .
|
-
-
- HY-N6576
-
|
|
Animals
Classification of Application Fields
Disease Research Fields
Steroids
Source Classification
Cancer
|
p38 MAPK
ERK
JNK
IAP
PARP
Apoptosis
Caspase
|
|
Hellebrigenin is an inhibitor that selectively targets the MAPK signaling pathway (ERK, p38, JNK) and XIAP, and can inhibit Akt expression and phosphorylation. Hellebrigenin can activate endogenous apoptosis pathways (such as mitochondrial membrane potential disruption, Caspase family activation, PARP cleavage), downregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) and upregulate pro-apoptotic proteins (Bax, Bak). Hellebrigenin can also induce DNA double-strand breaks to activate the ATM pathway. Hellebrigenin can inhibit tumor cell proliferation and clone formation, and is mainly used in the study of oral squamous cell carcinoma, liver cancer and other cancers .
|
-
-
- HY-W661499
-
|
|
Structural Classification
Productos naturales
Microorganisms
Source Classification
|
Phosphatase
Apoptosis
Reactive Oxygen Species (ROS)
Caspase
|
|
Orellanine, a nephrotoxic alkaloid found in Cortinarius orellanus, is an orally active and selective non-competitive inhibitor of alkaline phosphatase. Orellanine chelates iron, generates reactive oxygen species (ROS), induces DNA scission, forms ortho-semiquinone radicals, downregulates antioxidant defenses, and inhibits mitochondrial function. Orellanine induces caspase 8/9-mediated apoptosis. Orellanine inhibits synthesis of proteins, RNA, DNA, and mitochondrial protein synthesis, with metabolic activation required for cell-free protein synthesis inhibition. Orellanine can be used for the research of metastatic clear cell renal cell carcinoma, acute renal failure, chronic renal insufficiency, and kidney damage .
|
-
-
- HY-N1261
-
-
-
- HY-N0530
-
-
-
- HY-N15199
-
-
-
- HY-114594
-
-
-
- HY-N4308
-
|
Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone
|
Flavonols
Structural Classification
Flavonoids
other families
Classification of Application Fields
Plants
Disease Research Fields
Source Classification
Cancer
|
NF-κB
IKK
Bcl-2 Family
|
|
Hexamethylquercetagetin (Hexa-O-methylquercetagetin; Quercetagetin hexamethyl ether; 3,5,6,7,3',4'-Hexamethoxyflavone) is an orally active NF-κB inhibitor. Hexamethylquercetagetin inhibits NF-κB-derived luciferase activity, reduces phosphorylated p65 and IκBα, Cyclin D1, Bcl-2 and blocks TNFα-induced NF-κB activation. Hexamethylquercetagetin inhibits survival and proliferation of cervical carcinoma cells. Hexamethylquercetagetin suppresses tumor volume and weight in BALB/c nude mouse xenograft models of cervical carcinoma. Hexamethylquercetagetin can be used for the research of cancer, such as cervical carcinoma .
|
-
-
- HY-N0746R
-
-
-
- HY-17473R
-
|
Embelic acid (Standard); Emberine (Standard); NSC 91874 (Standard)
|
Quinones
Structural Classification
Benzene Quinones
Embelia laeta (Linn.) Mez
Plants
Myrsinaceae
Source Classification
|
Reference Standards
IAP
NF-κB
Apoptosis
Autophagy
|
|
Embelin (Standard) is the analytical standard of Embelin. This product is intended for research and analytical applications. Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC50=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .
|
-
-
- HY-N10009
-
|
|
Brosimopsis oblongifolia
Phenols
Polyphenols
Plants
Moraceae
Source Classification
|
NF-κB
TNF Receptor
COX
ERK
p38 MAPK
Sirtuin
|
|
Cudraflavone B is a prenylated flavonoid with anti-inflammatory and anti-tumor properties. Cudraflavone B is also a dual inhibitor of COX-1 and COX-2. Cudraflavone B blocks the translocation of nuclear factor κB (NF-κB) from the cytoplasm to the nucleus in macrophages. Thus, Cudraflavone B inhibits tumor necrosis factor α (TNFα) gene expression and secretion. Cudraflavone B also triggers the mitochondrial apoptotic pathway, activates NF-κB, the MAPK p38, and ERK, and induced the expression of SIRT1. Thus Cudraflavone B inhibits the growth of human oral squamous cell carcinoma cells .
|
-
-
- HY-N8380
-
|
|
Dalbergia hupeana Hance
Phenols
Polyphenols
Plants
Source Classification
Fabaceae
|
Apoptosis
Autophagy
PI3K
Necroptosis
|
|
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .
|
-
-
- HY-N12760
-
-
-
- HY-N3665
-
-
-
- HY-N2414R
-
-
-
- HY-N6726R
-
-
-
- HY-N2115R
-
-
-
- HY-N0864R
-
|
Macranthoiside I (Standard)
|
Triterpenes
Structural Classification
other families
Terpenoids
Plants
Source Classification
|
Reference Standards
Others
|
|
Macranthoidin B (Macranthoiside I) Standard is the analytical standard of Macranthoidin B (HY-N0864). This product is intended for research and analytical applications. Macranthoidin B (Macranthoiside I) is an orally active triterpene saponin. Macranthoidin B inhibits epithelial-mesenchymal transition in endometriosis via the COX‑2/PGE2 pathway, and also induces tumor cell apoptosis and inhibits their proliferation by regulating metabolism and increasing ROS levels . Macranthoidin B can be used in studies related to endometriosis, colorectal cancer and hepatocellular carcinoma .
|
-
-
- HY-N2217R
-
-
-
- HY-N6954R
-
-
-
- HY-116514R
-
-
-
- HY-N0566R
-
|
Anemosapogenin (Standard)
|
Triterpenes
Structural Classification
other families
Terpenoids
Plants
Source Classification
|
Reference Standards
Apoptosis
Autophagy
Bcl-2 Family
Caspase
Survivin
p38 MAPK
MMP
|
|
23-Hydroxybetulinic acid (Standard) is the analytical standard of 23-Hydroxybetulinic acid (HY-N0566). This product is intended for research and analytical applications. 23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer.
|
-
-
- HY-N17854
-
-
-
- HY-N18150
-
-
-
- HY-N19845
-
-
-
- HY-N11764
-
-
- HY-N18294
-
-
- HY-N8013
-
-
- HY-N17359
-
-
- HY-N17633
-
-
- HY-107272
-
-
- HY-W800535
-
|
|
Malvaceae
Structural Classification
Alkaloids
Sida acuta Burm. F.
Quinoline Alkaloids
Plants
Indole Alkaloids
Source Classification
|
NF-κB
p38 MAPK
mTOR
Topoisomerase
AMPK
Apoptosis
Cholinesterase (ChE)
HIF/HIF Prolyl-Hydroxylase
β-catenin
|
|
Cryptolepine is an orally active multi-potent alkaloid with anti-cancer, anti-bacterial, anti-viral, anti-malarial, anti-inflammatory, anti-hyperglycemic, relieve pain and other properties. Cryptolepine acts as an inhibitor of c-Myc, mTOR, NF-κB, HIF-1, MAPK and an activator of AMPKα1/2. It intercalates into DNA, inhibits topoisomerase II (Top II), disrupts mitochondrial dynamics and induces apoptosis. Cryptolepine also exhibits anti-plasmodial and cholinesterase inhibitory activities. Cryptolepine can be used in research related to tumors (melanoma, hepatocellular carcinoma, mammary adenocarcinoma, etc.), malaria, inflammatory diseases and diabetes, particularly in studies focused on inhibiting tumor growth and anti-plasmodial infection .
|
-
- HY-N19853
-
-
- HY-N17816
-
|
|
Structural Classification
Flavonoids
Flavones
Rutaceae
Plants
Zanthoxylum armatum DC.
Source Classification
|
Apoptosis
Reactive Oxygen Species (ROS)
α-synuclein
Succinate Dehydrogenase
Bcl-2 Family
Caspase
|
|
Tambulin is an orally active flavonol compound found in Zanthoxylum armatum. Tambulin can inhibit cell proliferation, induce apoptosis and inhibit ROS production. Tambulin upregulates cleaved caspase-3, cleaved caspase-9, and Bax, downregulates Bcl-2 levels. Tambulin can stimulate glucose-dependent insulin secretion and induce endothelium-independent vasorelaxation. Tambulin binds to succinate dehydrogenase (SDH) (Ki = 11.02 μM) and shows significant ferric reducing power. Tambulin can enhances oxidative stress resistance, reduces, lipofuscin deposits, lipid levels, α-synuclein levels, improves locomotary behavior, and dopamine levels in in age-synchronized L1 hermaphrodite Caenorhabditis elegans models of ageing and Parkinson's disease. Tambulin can be used for the researches of Parkinson's disease, lung squamous cell carcinoma, and diabetes .
|
-
- HY-N12378A
-
|
|
Structural Classification
Entada phaseoloides (L.) Merr.
Terpenoids
Labiatae
Sesquiterpenes
Plants
Source Classification
|
AMPK
FASTK
Sirtuin
ROCK
Keap1-Nrf2
Toll-like Receptor (TLR)
Apoptosis
PKA
ERK
NF-κB
Epigenetic Reader Domain
Caspase
|
|
α-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptotic agent. α-Patchoulene inhibits the NF-κB, TLR4, and cAMP/PKA/CREB signaling pathways; activates the Sirt1/Nrf2 and AMPK signaling pathways; and targets Fas/FasL, Caspase-3, ERK1/2, ROCK1/MLC2 for inhibition. α-Patchoulene regulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae. α-Patchoulene can be used in research related to various inflammatory, ischemic, fibrosis-associated diseases, as well as hepatocellular carcinoma .
|
-
| Cat. No. |
Nombre del producto |
Chemical Structure |
-
- HY-N6726S
-
|
|
|
Fumonisin B3- 13C34 is the 13C labeled Fumonisin B3 (HY-N6726). Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
|
-
-
- HY-17509S
-
|
|
|
Deracoxib-d3 (SC 046-d3; SC 59046-d3) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.
|
-
-
- HY-W654305
-
|
|
|
Palbociclib-d4 is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
|
-
-
- HY-Y1155S
-
|
|
|
Hexamethylphosphoramide-d18 is the deuterium labeled Hexamethylphosphoramide (HY-Y1155). Hexamethylphosphoramide is an orally active polar aprotic solvent, flame retardant additive, and carcinogen. Hexamethylphosphoramide undergoes cytochrome P-450-mediated N-demethylation to Formaldehyde. Hexamethylphosphoramide induces DNA-protein crosslinks. Hexamethylphosphoramide has been linked to nasal tumors (squamous cell carcinoma, adenoid squamous cell carcinoma), squamous metaplasia, rhinitis, tracheitis, and reversible and irreversible infertility .
|
-
-
- HY-13593S
-
|
|
|
Chlorambucil-d8 is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .
|
-
-
- HY-13593S1
-
|
|
|
Chlorambucil-d8-1 is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .
|
-
-
- HY-N6726S1
-
|
|
|
Fumonisin B3-13C34-1 is the isotopic internal standard of Fumonisin B3 (HY-N6726). Fumonisin B3 is an orally active fumonisin Mycotoxin. Fumonisin B3 can be isolated from Fusarium moniliforme, Fusarium proliferatum and Fusarium nygamai. Fumonisin B3 induces precancerous lesions, triggers embryonic death of chicken embryos, causes severe hemorrhage in dead chicken embryos. Fumonisin B3 can be used in studies related to hepatocellular carcinoma .
|
-
-
- HY-103018S
-
|
|
|
Gusacitinib-d4 (ASN-002-d4) is the deuterium labeled Gusacitinib (HY-103018). Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .
|
-
-
- HY-W703540
-
|
|
|
Deracoxib-d4 (SC 046-d4; SC 59046--d4) is deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.
|
-
| Cat. No. |
Nombre del producto |
Target |
Áreas de investigación |
Chemical Structure |
-
- HY-135146G
-
|
|
DNA Methyltransferase
Apoptosis
|
Cancer
|
|
GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma .
|
-
-
- HY-159642G
-
|
TYRA-300
|
FGFR
ERK
|
Metabolic Disease
Cancer
|
|
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
|
-
-
- HY-15947G
-
|
GDC-0994
|
ERK
c-Myc
Hexokinase
Lactate Dehydrogenase
|
Cancer
|
|
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Nombre del producto:
- Cat. No.:
- Cantidad:
- MCE Japan Authorized Agent:
